

TETIANA BRODIAZHENKO

RelA-SpoT Homolog enzymes
as effectors of Toxin-Antitoxin systems



TETIANA BRODIAZHENKO

RelA-SpoT Homolog enzymes
as effectors of Toxin-Antitoxin systems



UNIVERSITY OF TARTU

Press

Institute of Technology, Faculty of Science and Technology, University of Tartu,
Estonia

This dissertation was accepted for the commencement of the degree of Doctor of
Philosophy in biomedical engineering on October 14th, 2022 by the Council of
the Institute of Technology, Faculty of Science and Technology, University of
Tartu, Estonia.

Supervisors: Vasili Hauryliuk, PhD,
Institute of Technology, Faculty of Science and Technology,
University of Tartu, Tartu, Estonia

prof. Tanel Tenson, PhD,
Institute of Technology, Faculty of Science and Technology,
University of Tartu, Tartu, Estonia

Reviewer: Aivar Liiv, PhD
Institute of Molecular and Cell Biology, University of Tartu,
Tartu, Estonia

Opponent: prof. Tim R. Blower, PhD
Department of Biosciences, Durham University, Durham,
United Kingdom of Great Britain and Northern Ireland

Commencement: Auditorium 121, Nooruse 1, Tartu, Estonia on November 23rd,
2022 at 14:15.

Publication of this dissertation is granted by the University of Tartu, Estonia.

ISSN 2228-0855 (print)
ISBN 978-9916-27-047-9 (print)
ISSN 2806-2620 (pdf)
ISBN 978-9916-27-048-6 (pdf)

Copyright: Tetiana Brodiazhenko, 2022

University of Tartu Press
www.tyk.ee

TABLE OF CONTENTS

LIST OF ORIGINAL PUBLICATIONS	7
LIST OF ABBREVIATIONS	8
INTRODUCTION.....	10
REVIEW OF LITERATURE.....	11
1. Magic spot alarmone nucleotide (p)ppGpp	11
1.1. Discovery of the (p)ppGpp alarmone or the ‘magic spot’	11
1.2. Biological functions of (p)ppGpp: control of metabolism, growth rate, virulence and antibiotic tolerance	12
1.2.1. Direct transcriptional regulation by (p)ppGpp through allosteric control of the RNA polymerase: the <i>Escherichia coli</i> paradigm.....	14
1.2.2. Indirect transcription regulation by (p)ppGpp through control of nucleotide metabolism: the <i>Bacillus subtilis</i> paradigm	15
1.2.3. Regulation of protein synthesis by (p)ppGpp through regulation of expression of ribosome hibernation factors.....	16
1.3. Regulation of protein synthesis by (p)ppGpp through inhibition of translational GTPases	16
2. RelA-SpoT homolog (RSH) protein family	17
2.1. Evolutionary diversity of RelA-SpoT Homolog (RSH) protein family	17
2.2. Biological functions and molecular mechanisms of long RSHs Rel, RelA and SpoT.....	20
2.2.1. Housekeeping Small Alarmone Synthetase (SAS) RSH enzymes.....	21
2.2.2. toxSAS FaRel and Tas1: growth inhibition by (pp)pApp...	22
2.2.3. toxSAS FaRel2, PhRel, PhRel2 and CapRel: growth inhibition by tRNA CCA end pyrophosphorylation	23
2.3. Small Alarmone Hydrolases (SAH).....	24
3. Toxin-antitoxin (TA) systems	25
3.1. Classification of TA systems	25
3.2. Molecular mechanisms of controlled growth inhibition employed by TA systems.....	27
3.3. Specificity and promiscuity of toxin neutralization amongst class II TA systems	29
3.4. Biological functions of TA systems.....	30
AIMS OF THE STUDY	33

MATERIALS AND METHODS	34
1. Toxicity neutralization assay	34
2. Metabolic labelling.....	34
3. <i>In vitro</i> transcription-translation assays	35
3.1. Preparation of cell-free translational extracts	35
3.2. Cell-free transcription-translation reactions and luciferase assay.....	36
RESULTS AND DISCUSSION	38
I. toxSAS FaRel2, PhRel, PhRel2 and CapRel pyrophosphorylate tRNA CCA end to abrogate the tRNA aminoacylation (Paper I).....	38
II. Panacea: a hyperpromiscuous antitoxin protein domain involved in neutralization of diverse toxin domains (Paper II).....	40
III. Elimination of ribosome inactivating factors improves the efficiency of protein production in yeast and <i>B. subtilis</i> in vitro translational lysates (Paper III)	46
CONCLUSIONS	49
REFERENCES.....	50
SUMMARY IN ESTONIAN	61
ACKNOWLEDGMENTS.....	63
PUBLICATIONS	65
CURRICULUM VITAE	125
ELULOOKIRJELDUS.....	127

LIST OF ORIGINAL PUBLICATIONS

The current dissertation is based on the following original publications which are referred to by their Roman numerals:

- I. Kurata T, **Brodiazhenko T**, Alves Oliveira SR, Roghanian M, Sakaguchi Y, Turnbull KJ, Bulvas O, Takada H, Tamman H, Ainelo A, Pohl R, Rejman D, Tenson T, Suzuki T, Garcia-Pino A, Atkinson GC, Hauryliuk V. RelA-SpoT Homolog toxins pyrophosphorylate the CCA end of tRNA to inhibit protein synthesis. *Molecular Cell*. 2021 Aug 5; 81(15):3160-3170.e9.
- II. Kurata T, Saha CK, Buttress JA, Mets T, **Brodiazhenko T**, Turnbull KJ, Awoyomi OF, Oliveira SRA, Jimmy S, Ernits K, Delannoy M, Persson K, Tenson T, Strahl H, Hauryliuk V, Atkinson GC. A hyperpromiscuous anti-toxin protein domain for the neutralization of diverse toxin domains. *Proceedings of the National Academy of Sciences of the United States of America*. 2022 Feb 8; 119(6):e2102212119.
- III. **Brodiazhenko T**, Johansson MJO, Takada H, Nissan T, Hauryliuk V, Murina V. Elimination of Ribosome Inactivating Factors Improves the Efficiency of *Bacillus subtilis* and *Saccharomyces cerevisiae* Cell-Free Translation Systems. *Frontiers in Microbiology*. 2018 Dec 18; 9:3041.

Author's contributions:

In paper I and II I have performed metabolic labelling assays and as well as plate toxicity-neutralization assays. I participated in writing the original draft and preparation of figures. In paper III I have prepared and characterised bacterial and yeast cell-free translation systems. I performed all the experiments presented in the paper except for the polyribosome profiling. I participated in writing the original draft and preparation of figures.

LIST OF ABBREVIATIONS

AA	Amino Acid
ADPr	ADP-ribose
BCAA	Branched-Chain Amino Acids
CFU	Colony Forming Units
DNA	Deoxyribonucleic acid
DTT	Dithiothreitol
DUF	Domain of Unknown Function
GDP	Guanosine diphosphate
GTP	Guanosine triphosphate
HD	Hydrololase domain
HPLC	High Performance Liquid Chromatography
HPF	Hibernation Promoting Factor
LA	Luria Agar
LB	Lysogeny broth
MS	Magic Spot
mRNA	messenger RNA
ppApp	adenosine 5'-diphosphate 3'-diphosphate
pppApp	adenosine 5'-triphosphate 3'-diphosphate
(p)ppGpp	guanosine-5'-(tri)diphosphate 3'-diphosphate
ppGpp	guanosine-5'-diphosphate 3'-diphosphate
pppGpp	guanosine-5'-triphosphate 3'-diphosphate
(p)ppGpp ⁰	bacterial strain lacking (p)ppGpp
IF2	Initiation Factor 2
PanA	Panacea Antitoxin
PanAT	Panacea Antitoxin-Toxin system
PanT	Panacea Toxin
PP	Pyrophosphate group
RC	RNA control locus
RLU	relative luminescence unit
RMF	ribosome modulation factor
RNA	Ribonucleic acid
rRNA	Ribosomal RNA
RNAP	RNA polymerase
ROS	Reactive Oxygen Species
RSH	RelA/SpoT Homolog
SAH	Small Alarmones Hydrolase
SAS	Small Alarmones Synthetase
SD	Shine-Dalgarno
SR	Stringent Response

ssDNA	single stranded DNA
SYNTH	Synthetase domain
TA	Toxin-Antitoxin
TCA	Trichloroacetic acid
toxSAS	toxic Small Alarmone Synthetase
TLC	Thin Layer Chromatography
tRNA	Transfer RNA
T6SS	type 6 secretion system
WT	Wild-Type

INTRODUCTION

Bacteria use numerous mechanisms to cope with adverse conditions. Nucleotide signalling molecules called alarmones are important players in bacterial adaptation. The well-studied alarmone guanosine (penta)tetraphosphate (p)ppGpp regulates cellular metabolism and growth in response to nutrient limitations. The less-understood adenosine (penta)tetraphosphate (p)ppApp is both used as a toxin poisoning cells through secretion system and as an effector of intracellular toxin-antitoxin (TA) systems. RelA-SpoT Homologue (RSH) enzymes mediated both the synthesis and degradation of alarmones.

Using computational tool FlaGs (standing for Flanking Genes) we have identified five unusual families of single-domain RSH enzymes – so-called Small Alarmone Synthetases (SASs) – that were encoded in two-gene operons, something that serves as a hallmark of TA systems. As these SAS were exceedingly toxic when expressed in *Escherichia coli*, and therefore we have dubbed these as toxic SAS, toxSAS. We have uncovered the mechanism of toxSAS-mediated growth defect. FaRel toxSAS from *Cellulomonas marina* inhibits the growth by synthesising (p)ppApp, while the other toxSAS are not able to produce alarmones. Instead, they abrogate protein synthesis through pyrophosphorylation of the 3'CCA end of tRNA.

PhRel2 toxSAS antitoxin, ATphRel2, it is a two-domain protein. Using FlaGs we discovered that of the two domains, initially referred as Domain of Unknown Function 4065, DUF4065, is present in numerous antitoxins in TA systems of bacteria, archaea and bacteriophages. We have experimentally validated several DUF4065-containing TA systems and characterised the mechanism of toxicity employed by the nonhomologous toxins. We have renamed the DUF4065 domain to Panacea, after the Greek goddess of universal cure. Our results suggests that Panacea is an adaptable domain that can evolve to neutralize and become specific for a range of various toxin domains. We dubbed this feature of Panacea as hyper-promiscuity.

Finally, in my PhD thesis work I have studied an adaptation mechanism that is employed by both eukaryotes and bacteria to throttle their translational capacity when nutrients are not available by forming inactive ribosomal dimers. In bacteria formation of ribosomal dimers is induced by (p)ppGpp alarmone nucleotide, which, in turn, induces the expression of ribosome dimerization or hibernation factor (HFP). My main focus was developing more active translation lysates from yeast and bacterial strains that lack the capacity to form ribosomal dimers, the hypothesis being that these will have higher concentration of active ribosomes and, therefore, will yield more active lysates. My experiments demonstrated that yes, indeed, genetic ablation of ribosomal dimerization results in improved activity of lysates.

REVIEW OF LITERATURE

1. Magic spot alarmone nucleotide (p)ppGpp

Like all living organisms, bacteria sense the environment and respond to plethora of stresses by adjusting their physiology accordingly (Cashel, 1975; Fernández-Coll L., 2020; Hobbs and Boraston, 2019; Potrykus and Cashel, 2008). One of the central bacterial stress pathways is the stringent response (SR) (Hauryliuk et al., 2015). The stringent response mediates the bacterial adaptation to nutrient limitation as well as in response to abiotic environmental stresses like heat shock (Anderson et al., 2021; Schäfer H., 2020). More than six decades ago alarmone nucleotides ppGpp and pppGpp – collectively referred to as (p)ppGpp – or the “magic spots” were discovered to be produced in *Escherichia coli* cells as a response to amino acids limitation (Cashel and Gallant, 1969). The first physiological role of the SR to be characterised was inhibition of stable RNA (rRNA and tRNA) synthesis, coordinated with induction of expression of genes involved in amino acid biosynthesis and stress tolerance (Potrykus and Cashel, 2008). However, decades of research have established that in addition to transcription, (p)ppGpp targets multiple other processes in the cell, such as translation, ribosome assembly, metabolism, and impact all the aspects of cell physiology including adaptation to nutrient limitation, antibiotic resistance and virulence (Travis and Schumacher, 2021).

1.1. Discovery of the (p)ppGpp alarmone or the ‘magic spot’

Investigations of the molecular mechanisms of the stringent response started with identification of so-called RNA control locus (RC) – a chromosomal locus that is crucial for regulation of ribosomal RNA synthesis in response to amino acid starvation. While a mutant *E. coli* RC harbouring the RC^{rel} (“relaxed”) allele are unable to suppress rRNA synthesis upon amino acid starvation, “stringent” (RCst) strains readily repress rRNA production when starved (Stent and Brenner, 1961). Several years later Cashel and Gallant discovered that amino acid starvation leads to appearance of two previously unknown compounds – dubbed as the magic spots I and II, MS I and II – when cellular nucleotide pools are resolved on Thin Layer Chromatography (TLC) (Cashel and Gallant, 1969). Analysis of MS I revealed that it is a highly pyrophosphorylated nucleotide that contains guanine, ribose and phosphate in molar ratios 1:1:4 (Cashel, 1970), and the following chemical structure of MSI/ppGpp was put forward: guanosine-5'-diphosphate 3'-diphosphate. Soon after the structure of pppGpp/MS II was also established, demonstrating that it a close relative of ppGpp – guanosine-5'-triphosphate-3'-diphosphate (Erlich H., 1971). Finally, it was uncovered that pppGpp is synthesised from GTP (**Figure 1**), and the reaction is catalysed by the product of RC locus – a protein called RelA – on ‘starved’ ribosomes harbouring deacylated tRNA in the A-site (Haseltine and Block, 1973).

The other *E. coli* enzyme mediating in both (p)ppGpp synthesis and degradation is SpoT (**Figure 1**) (Sy, 1977). Together with RelA, SpoT is a founding member of the RelA SpoT Homolog (RSH) protein family (Atkinson et al., 2011). While the (p)ppGpp synthetase (SYNTH) activity of RelA is specifically induced by only one metabolite limitation signal – amino acid starvation – SYNTH activity of SpoT is activated by numerous inputs, such as carbon (Hernandez, 1991; Murray, 1996), fatty acid (Seyfzadeh et al., 1993) and iron (Murray, 1996) limitations. In addition to relatively weak SYNTH activity, SpoT possesses a strong (p)ppGpp hydrolysis (HD) activity, thus balancing the (p)ppGpp production by RelA (Xiao et al., 1991). Finally, pppGpp is converted to ppGpp through the catalytic action of guanosine-5'-triphosphate-3'-diphosphate pyrophosphatase (GppA), an enzyme found in many Gram-negative species such as *E. coli* (Mechold et al., 2013).




Figure 1. The cycle of (p)ppGpp synthesis and degradation in *E. coli*. Guanosine tetraphosphate ppGpp/MSI, is synthesized from ATP and GDP, while guanosine pentaphosphate, pppGpp/MSII, is formed from ATP and GTP, respectively. The (p)ppGpp synthesis is catalysed by strong SYNTH activity of RelA and weak SYNTH activity of SpoT, potent HD activity of SpoT responsible for (p)ppGpp degradation. Adapted from (Hauryliuk et al., 2015).

In the following chapters I will focus on the role of (p)ppGpp as a master regulator of bacterial metabolism and gene expression.

1.2. Biological functions of (p)ppGpp: control of metabolism, growth rate, virulence and antibiotic tolerance

The alarmone has numerous molecular targets in bacterial cell, with some of mechanisms of regulation differing between Gram-positive and Gram-negative species. The targets are summarised on **Figure 1**. In this chapter I will give an overview of (p)ppGpp-mediated control of cellular metabolism and gene expression, and in the following chapters I will discuss the individual regulatory pathways one by one.

While acute starvation or heat shock leads to a spike in (p)ppGpp alarmone levels that causes will inhibition of bacterial growth and protein synthesis, with the cell entering a ‘survival mode’ (Svitil A. L., 1993), the low basal level of (p)ppGpp under balanced growth condition is essential for maintenance efficient cellular metabolism and adjustment of it to growth rate (Fernández-Coll L., 2020). An example of (p)ppGpp playing a key role in metabolic control, is. direct regulation of GTP synthesis though the alarmone binding to HprT and GmK *B. subtilis* (Anderson B. W., 2019; Kriel et al., 2012).

Bacteria profoundly modulate their gene expression in response to changing environmental conditions (Fernández-Coll L., 2020; Hauryliuk et al., 2015; Yoshida and Wada, 2014), with expression growth-related genes being down-regulated and the survival program engaged under stress (Potrykus and Cashel, 2008; Ross et al., 2016). The effect of (p)ppGpp on gene expression is well-studied in Gamma proteobacteria (currently Pseudomonadota by (Oren, 2021)) such as *E. coli* (Haugen, 2008). In this bacterium (p)ppGpp controls expression of more than 700 genes involved in translation machinery, rRNA synthesis, amino acid biosynthesis and others (Durfee, 2008; Haugen, 2008; Ross et al., 2013; Traxler, 2008). While acting on the same target genes, ppGpp is more potent regulator than pppGpp (Bruhn-Olszewska et al., 2018; Mechold et al., 2013).




Figure 2. Main targets of (p)ppGpp in Gram-positive and Gram-negative bacteria.

By binding to the DNA primase (p)ppGpp suppresses DNA replication both in Gram-negative or at the and Gram-positive bacteria (Giramma et al., 2021; Maciag et al., 2010). To modulate transcription in a promotor-specific manner, in Gram-negative bacteria (p)ppGpp binds directly to RNAP together with the DksA (Paul et al., 2005; Ross et al., 2013); (p)ppGpp-mediated repression or activation of target gene are determined by the discriminator elements in the promoter region (Wagner, 2002). Additionally, Gram-negative bacteria (p)ppGpp regulates transcription indirectly by affecting the sigma factor usage (Traxler, 2011). In Gram-positive bacteria (p)ppGpp regulates transcription indirectly through depletion of the GTP pool (Paul et al., 2004). Furthermore, low GTP levels cause CodY de-repression, promoting the transcription of genes involved in amino acid biosynthesis, nutrient transport and virulence (Kriel et al., 2012). Both in Gram-negative and Gram-positive bacteria (p)ppGpp competes with GTP by directly binding to and inhibiting translational GTPases, such as initiation factor 2 (IF2) and elongation factor G (EF-G) (Milon, 2006). This results in suppression of protein synthesis upon (p)ppGpp accumulation. Adapted from (Gaca et al., 2015).

In addition to controlling metabolism and growth rate, (p)ppGpp plays a key role in bacterial virulence and antibiotic tolerance (Fernández-Coll L., 2020). Genetic disruption of the RSH genes in *Salmonella enterica* serovar Typhimurium results in the so-called (p)ppGpp⁰ strain which is avirulent and non-invasive in infection models (Pizarro-Cerdá J., 2004). Similarly, (p)ppGpp is implicated in virulence of opportunistic pathogenic *E. coli* (Aberg A., 2009; Aberg A., 2008; Cabrer-Panes J. D., 2020). (p)ppGpp was also suggested to be implicated in formation of the antibiotic-tolerant sub-population of bacterial culture – the so-called persisters (Svenningsen M. S., 2019). However, the mechanism underlying persister formation and the exact role of (p)ppGpp in the process are still unclear (Kaldalu N., 2020). Since the stringent response and (p)ppGpp-mediated signalling are important in bacterial virulence and antibiotic tolerance, RSH enzymes are currently being explored as potential targets for development of novel antibacterials (Fernández-Coll L., 2020).

1.2.1. Direct transcriptional regulation by (p)ppGpp through allosteric control of the RNA polymerase: the *Escherichia coli* paradigm

Mechanistic studies of transcriptional regulation in *E. coli* have resulted in uncovering the regulatory paradigm of (p)ppGpp-mediated transcriptional regulation through direct alarmone binding to RNA polymerase (RNAP), which modulates transcription initiation activity in a promoter-specific way (Haugen, 2008). Importantly, in addition to RNAP itself, this regulation involves a transcriptional factor – DksA, a negative regulator of rRNA expression and positive regulator of amino acid biosynthesis promoters (Edwards, 2011). When tested in reconstituted transcription system, DksA dramatically potentiates the regulatory effect of (p)ppGpp on RNAP (Paul et al., 2004). Structural studies have revealed the mechanistic underpinnings of this synergistic regulation. (p)ppGpp binds to two separate sites on *E. coli* RNA polymerase (**Figure 3**) (Ross et al., 2016) The (p)ppGpp binding site 1 of *E. coli* RNAP is located at the interface of β' and ω subunits (Ross et al., 2013) and does not require DksA (Ross et al., 2016). The Site 1 is responsible for effects on transcription initiation *in vivo* when ppGpp concentrations are low, such as during growth in rich medium or early starvation response. Conversely, the Site 2 is formed by both the DksA and RNAP β' subunit and when (p)ppGpp concentrations are high, the alarmone can populate Site 2 in addition to high-affinity Site 1 (Ross et al., 2016). Site 1 is well-conserved in Pseudomonadota but not in other bacterial phyla (Ross et al., 2013). Similarly, distribution of DksA homolog is also limited to proteobacterial species (Ross et al., 2016).




Figure 3. Location of (p)ppGpp Sites 1 and 2 on *E. coli* RNAP with 1 and 2. RNAP (marine green), (p)ppGpp (pink), DksA (rainbow). Adapted from (Ross et al., 2016), PDB code 5VSW.

1.2.2. Indirect transcription regulation by (p)ppGpp through control of nucleotide metabolism: the *Bacillus subtilis* paradigm

Gram-positive bacteria – such as Firmicute (currently Bacillota by (Oren, 2021)) *B. subtilis* (p)ppGpp – employ an alternative, indirect, mechanism to control transcription during stringent response (Krasny and Gourse, 2004). In these species the alarmone binds and inhibits enzymes which are involved in GTP synthesis, such as the guanylate kinase (GMK) (converts GMP to GDP), HprT (converts hypoxanthine to IMP and guanine to GMP) GuaB (converts IMP to XMP) (Lopez, 1981), which results in decreased GTP levels (Kriel et al., 2012). Conversely, in the absence of (p)ppGpp-mediated suppression of GTP biosynthesis, (p)ppGpp⁰ *B. subtilis* strain has decreased viability due to abnormally high levels of GTP (Kriel et al., 2014). Since GTP acts as an initiator nucleotide (NTP_i) for rRNA promoters in *B. subtilis*, the reduction of the GTP concentration leads to repression of the rRNA production (Krasny and Gourse, 2004; Liu et al., 2015).

Additionally, in Bacillota (p)ppGpp-mediated depletion of the GTP acts by affecting transcriptional repressor CodY (Geiger, 2014). Decrease of the GTP level destabilises the interaction between CodY and DNA (Sonenshein, 2007). Destabilisation CodY-DNA complex leads to de-repression of transcription of numerous genes involved in metabolism (Belitsky, 2013; Slack, 1995), including the ones responsible for the synthesis of the branched-chain amino acids (BCAA) (isoleucine, leucine, and valine) (Molle, 2003), as well as threonine and arginine (Belitsky, 2013).

1.2.3. Regulation of protein synthesis by (p)ppGpp through regulation of expression of ribosome hibernation factors

Protein synthesis is an energy-costly process which is repressed under conditions of stress and nutrient limitation (Yoshida and Wada, 2014). In bacteria the large (50S) and the small (30S) ribosomal subunits form together functional 70S ribosome. In eukaryotes, 60S and 40S ribosomal subunits form 80S ribosomes (Rodnina, 2018). Formation of inactive ribosomal dimers – 100S (in bacteria) or 110S (in eukaryotes) – is one of the mechanisms that mediates translational repression upon stress (Yoshida and Wada, 2014). In Gamma-pseudomonadota such as *E. coli* three factors are involved in the 100S formation: ribosome modulation factor (RMF), short version of the hibernation promoting factor (HPF), and YfiA (Izutsu, 2001; Lazzarini, 1971; Wada A., 1990). Most of other bacterial lineages encode only one factor, a long version of HPF (Yoshida and Wada, 2014). When environmental conditions improve, the ribosome dimers dissociate back from inactive 100S form to active 70S ribosomes (Aiso, 2005; Yamagishi, 1993). For example, 100S dissociate when stationary phase cells are transferred to fresh nutrient-rich growth media (Aiso, 2005). Transcription of *rmf* gene in *E. coli* is controlled by (p)ppGpp, thus directly connecting ribosomal dimerization to the stringent response (Kaczanowska, 2007). Similarly, in cyanobacteria (like *Synechococcus*) increased level of (p)ppGpp during transition from light condition to dark control long *hpf* expression to suppress translation by forming 100S ribosome dimers.

1.3. Regulation of protein synthesis by (p)ppGpp through inhibition of translational GTPases

Translation initiation in bacteria involves three initiation factors (IFs): IF1, translational GTPase IF2 and IF3 (Rodnina, 2018; Vinogradova et al., 2020). In its GTP-bound form IF2 promotes the association of initiator tRNA (fMet-tRNA_i^{Met}) to small ribosomal subunit (30S) to initiate the protein synthesis (Goyal, 2015; Milon, 2010). By competing with IF2's natural substrate, GTP, (p)ppGpp inhibits the activity of translational GTPase, and therefore, suppresses translation initiation (Milon, 2006; Vinogradova et al., 2020). While ppGpp can bind and inhibit other translational GTPases as well – such as EF-G which catalyses ribosomal elongation and recycling – affinity of ppGpp to IF2 is higher than to EF-G, which renders IF2 the primary target (Mitkevich, 2010). The ppGpp concentration can rise to millimolar concentration upon acute stringent response and exceed that of GTP (Varik et al., 2017), resulting in efficient suppression of initiation translation initiation. Finally, (p)ppGpp also binds to and inhibits GTPases RsgA, RbgA, Era and ObgE that are involved in ribosomal assembly, thus throttling the ribosomal production upon nutrient limitation (Corrigan et al., 2016).

2. RelA-SpoT homolog (RSH) protein family

More than 50 years is past after discovery of stringent response by (Stent and Brenner, 1961) and effector molecule (p)ppGpp (Cashel and Gallant, 1969). The question which remains open was synthesis of (p)ppGpp. How is it synthesized? What kind of enzymes are involved in synthesis? To answer these questions, we should have a look at the previous studies. First authors who demonstrated that synthesis of (p)ppGpp requires deacylated tRNA, 30S and 50S ribosomal subunits and messenger RNA as a template were Haseltine and Block in 1973. They also proved that ppGpp and pppGpp are not synthesized in vitro if translation machinery (ribosome) is occupied by protein production (Haseltine and Block, 1973). The stringent elements like RelA responsible for production of (p)ppGpp (Cashel, 1975) and SpoT for its hydrolyzation (Sy, 1977) respectively.

The *relA* and *spoT* genes are not the only ones which are involved in (p)ppGpp metabolism. These proteins are part a protein family which is called RelA-SpoT homolog or RSH family. In the next chapter will be described the evolution and variety of RSH proteins in the tree of life.

2.1. Evolutionary diversity of RelA-SpoT Homolog (RSH) protein family

RelA/SpoT Homologue (RSH) proteins regulate the concentration of the alarm-one nucleotides ppGpp and pppGpp. Members of the RSH superfamily can be divided into long RSHs (Rel, RelA and SpoT) and short RSHs, with the latter being sub-divided in Small Alarmone Synthetases (SAS) and Small Alarmone Hydrolases (SAH). The long RSHs are large multidomain proteins, while the short RSHs typically contain only one domain– either (p)ppGpp synthesis (SYNTH) or hydrolysis (HD) domain (Atkinson et al., 2011) (**Figure 5**). The N-terminal enzymatic region (NTD) of long RSHs consists of SYNTH (sometimes referred to as pseudo-SYNTH in the case of SYNTH-inactive RelA) and HD (sometimes referred to as pseudo-HD in the case of HD-inactive *Moraxellaceae* SpoT) domains. The regulatory multi-domain carboxy-terminal (CTD) domain region is comprised of Thr-tRNA synthetase, GTPase and SpoT domain (TGS), the Helical domain, the Zing Finger Domain (ZFD) [alternatively referred to as Conserved Cysteine, CC], and, finally, the RNA Recognition Motif (RRM) [alternatively referred to as Aspartokinase, Chorismate mutase and TyrA, ACT] domains (Atkinson et al., 2011).




Figure 5. Domain organization of long and short RSH proteins. Long RSH proteins are made up of six domains: (p)ppGpp hydrolysis domain (HD), (p)ppGpp synthesis domain (SYNTH), TGS (Threonyl-tRNA synthetase, GTPase, SpoT), Helical, ZFD and RRM. Grey boxes shown the N-terminal region (NTD), blue boxes shown the C-terminal domain region (CTD). Th the case of RelA the HD domain is enzymatically inactive (sometimes referred to as pseudo-SYNTH), which is marked with a red cross. The SYNTH domain for SpoT has weak enzymatic activity, marked with dashed line. Adapted from (Haurlyliuk et al., 2015).

The pair of the SYNTH-only stringent factor RelA and bifunctional – that is capable of both syntheses and degradation of (p)ppGpp – SpoT is found exclusively in Gamma- and Beta-pseudomonadota (Atkinson et al., 2011; Mittenhuber, 2001) (**Figure 4**). The most of other bacterial genomes carry one bifunctional long RSH: the ancestral stringent factor Rel (Atkinson et al., 2011; Mittenhuber, 2001) (**Figure 4**). Just as in the course of evolution RelA has lost its HD function and became a SYNTH-only factor, in *Moraxellaceae* SpoT has lost its (originally weak) SYNTH function (Williams, 2010). The loss of RelA resulting in SpoT-only bacteria is a rare event, that seemingly has occurred in *Acidithiobacillus ferrooxidans*, *Candidatus Ruthia magnifica*, *Methylovorus* SIP and *Nitrosomonas europaea*. In these species it seems that SpoT, similarly to bifunctional Rel, is the sole bifunctional (p)ppGpp synthetase and hydrolase (Atkinson et al., 2011). Members of the PVC superphylum (plantomycetes, verrucomicrobia and chlamydiales) seem to lack long RSHs altogether (Atkinson et al., 2011; Mittenhuber, 2001). These are mainly intracellular endosymbionts and pathogens like *Neorickettsia*, *Rickettsia*, *Bifidobacterium* and *Anaplasma* (Atkinson et al., 2011). Long RSH genes are also undetectable in genomes of *Mycoplasma* spp., three of *Spirochetes* species as well as *Thermoanaerobacter* X514 of *Clostridiales*.




Figure 5. Evolution of long RSH proteins in different bacterial clades. While γ - and β -Proteobacteria encode pair of long RSHs – RelA (a strong ribosome-associated (p)ppGpp synthetase) and SpoT (bifunctional RSH capable of both hydrolysis and synthesis of (p)ppGpp), most of the clades encode only one long RSH, bifunctional Rel. On the lineage to γ - and β -Proteobacteria (currently Pseudomonadota) Rel underwent gene duplication, giving rise to RelA and SpoT. In some lineages no long RSHs are present (chlamydiales, verrucomicrobia and plantomycetes, PVC). Adapted from (Atkinson et al., 2011).

The first SASs to be discovered are housekeeping single domain synthetases RelQ and RelP encoded in *B. subtilis* genome (Nanamiya et al., 2008). Subsequently RelQ and RelP were studied in detail (Beljantseva et al., 2017; Manav et al., 2018; Steinchen et al., 2018). Recently our lab discovered that some subfamilies of SASs are encoded in conserved bicistronicity organisation and act as toxic effectors – toxSAS – of toxin-antitoxin (TA) systems (Jimmy et al., 2020). This discovery and TAs in general are discussed in a separate chapter of this thesis. While SAH are relatively well studied, SAHs are less well understood, with, arguably, most well-studied representative being is eukaryotic SAH MESH1 (Atkinson et al., 2011).

2.2. Biological functions and molecular mechanisms of long RSHs Rel, RelA and SpoT

In 1973 Haseltine and Block uncovered the biochemical basis of (p)ppGpp accumulation in *E. coli* upon amino acids starvation by demonstrating that the presence of uncharged (deacylated) tRNA in the ribosomal A site serves as the inducer of RelA's SYNTH enzymatic activity (Haseltine and Block, 1973). Recent cryo-EM reconstructions (Arenz et al., 2016; Brown et al., 2016; Loveland et al., 2016) and biochemical studies (Roghianian et al., 2021; Takada et al., 2021) have uncovered the molecular mechanism of the ribosome-mediated RelA activation in great detail. Upon amino acid starvation, 'hungry' ribosomes with empty A site accumulate as well as deacylated tRNAs cognate to the A-site codon of hungry ribosomes. The regulatory C-terminal domains of RelA recruit the stringent factor to the hungry A-site, which is followed by the recruitment of the deacylated tRNA, leading to full activation of RelA's SYNTH enzymatic activity (**Figure 6**).




Figure 6. Mechanism of RelA activation by the starved ribosomal complexes. The C-terminal domains of RelA, the ZFD and RRM, bind the vacant A site of the hungry ribosome. The NTD remains outside of the A site. The A-site-cognate deacylated tRNA is then recruited by RelA to the ribosomal at the A site. The allosteric signal for the CTD is transferred to the NTD, activating the SYNTH function of RelA. Adapted from (Loveland et al., 2016).

In addition to starved ribosomal complexes, the SYNTH activity of both RelA (Shyp et al., 2012) and Rel (Takada et al., 2021) enzymes is also stimulated by the very enzymatic product synthesised by these RSHs, the alarmone (p)ppGpp. Detailed mechanistic understanding of this regulatory mechanism was uncovered in 2021 (Roghianian et al., 2021). In the absence of the alarmone, the NTD of RelA/Rel assumes a compact conformation in which the pseudo-HD/HD inhibits the SYNTH domain. (p)ppGpp binding to an allosteric site located in the hinge region that connects pseudo-HD/HD and SYNTH domains drives the transition to an open conformation of the NTD which is – unlike the HD-primed closed one – is compatible with the SYNTH activity (Roghianian et al., 2021). Finally, activation by the alarmone and activation by the ribosomal starved complex synergise, resulting in full activation of the (p)ppGpp production (Roghianian et al., 2021).

As discussed above, bifunctional RSHs Rel and SpoT control (p)ppGpp level in the cell via two active sites – one with hydrolase function and another synthetase (Avarbock et al., 2000; Hogg et al., 2004). SpoT is metalloenzyme, with

Mn²⁺ being essential for its HD activity (Hogg et al., 2004). It is not clear if SpoT is activated by stalled ribosome complexes (Gentry, 1995; Jiang, 2007). While SpoT senses and is regulated by numerous stress conditions like fatty acid (Seyfzadeh et al., 1993; Sinha, 2019), carbon (Xiao et al., 1991) or iron (Vinella, 2005) limitation, the exact mechanism of sensing and activation is unclear. Unlike SpoT – and similarly to RelA – activation of the Rel’s SYNTH is mediated by starved ribosomes (Avarbock et al., 2000). Similarly, to SpoT, the hydrolysis function is also strictly dependant on the Mn²⁺ cofactor (Avarbock et al., 2000; Hogg et al., 2004; Van Nerom et al., 2019).

2.2.1. Housekeeping Small Alarmone Synthetase (SAS) RSH enzymes

Short Alarmone Synthetases (SAS) are monofunctional enzyme performing synthesis of alarmone nucleotides (Atkinson et al., 2011; Steinchen et al., 2018). The most well-studied ‘housekeeping’ SAS representatives are RelQ (also known as SAS1, YjbM) and RelP (also known as SAS2, YwaC) (Atkinson et al., 2011; Beljantseva et al., 2017; Nanamiya et al., 2008; Ruwe et al., 2017; Steinchen et al., 2015; Steinchen et al., 2018). While the enzymatic output of long RSHs is predominantly regulated through binding to and regulation by other components of the cell (such as starved ribosomes), activity of SAS enzymes is largely regulated on transcriptional level. In *Enterococcus* species treatment with cell wall-targeting antibiotic vancomycin was shown to trigger the transcriptional induction of RelQ expression, resulting in (p)ppGpp overproduction, thus conferring tolerance to the antibiotic (Abranches et al., 2009). Similarly, transcription-driven SAS overexpression is implicated in cell envelope stress response in *Staphylococcus aureus* (Geiger et al., 2014; Tagami, 2012).

X-ray crystallography studies have revealed that *B. subtilis* RelQ and RelP (Steinchen et al., 2015) and *Staphylococcus aureus* RelP (Steinchen et al., 2018) assemble into homotetramer (**Figure 7**). Surprisingly, just like the SYNTH activity of Rel/RelA is regulated by the alarmone, RelQ is also allosterically regulated by pppGpp, so is RelP – but the molecular mechanism is completely different and evolutionally unrelated: in the case of SAS, the allosteric site is formed on the interface between the subunits (Steinchen et al., 2015). Finally, RelP from *Staphylococcus aureus* was shown to have a putative Zn²⁺ binding site and is inhibited by Zn²⁺ ions in vitro (Manav et al., 2018). The enzyme was proposed to be activated as decrease in the intracellular zinc level in response to oxidative stress, thus ablating the inhibition by the metal ions (Steinchen et al., 2018).




Figure 7. Tetrameric structure of *S. aureus* RelP SAS. Allosteric regulator pppGpp is shown in red. Adapted from (Manav et al., 2018), PDB code 6EX0.

2.2.2. toxSAS FaRel and Tas1: growth inhibition by (pp)pApp

The initial indications of some SAS representatives being specifically toxic for the cell came from a study that focused on a protein pair – SAS gp29 and its antidote protein gp30 – encoded in a mycobacterial bacteriophage Phrann (Dedrick et al., 2017). It was found the gene gp29 product is highly toxic to *Mycobacterium smegmatis* cells, while co-expression of the protein product of the gp29-neighbouring gene gp30 neutralised the toxic effect (Dedrick et al., 2017). As bacterial cells carrying gp29-gp30-encoding Phrann prophage were resistant to coinfection by other bacteriophages, such as Tweety and Gaia, Dedrick and colleagues concluded that the gp29 and gp30 gene pair may play a role in the phage defence mechanism. However, the mechanism of gp29-mediated toxicity and phage defence were not experimentally established. Note that conserved bicistronic (two-gene) architecture of gp29-gp30, with one gene being toxic and the other neutralising the toxic effect, is characteristic for so-called toxin-antitoxin pairs (TA). However, this connection was not made in the original paper (Dedrick et al., 2017).

In 2019 a highly divergent RSH SAS enzyme Tas1 was shown to be a secreted toxic effector of *Pseudomonas aeruginosa* type 6 secretion system (T6SS) that synthesises (pp)pApp nucleotides – pApp, ppApp and pppApp – using AMP, ADP and ATP as substrates, respectively (Ahmad et al., 2019). Production of (p)ppApp by Tas1 injected into the prey cell via T6SS results in depletion of the ATP pool, with the toxic effect mediated through the inhibition of the activity of PurF enzyme involved in purine synthesis pathway (Ahmad et al., 2019).

In parallel, our lab has developed a computational tool FlaGs (from Flanking Genes) which allows analysing gene neighbourhoods to identify conserved operon

structures (Saha et al., 2021). Since TAs are encoded in conserved bicistronic operons, we used the tool to discover five new TA-like SASs subfamilies: FaRel, PhRel2, FaRel2, PhRel and CapRel (Jimmy et al., 2020). One representative of each subfamily was taken for experimental investigations – *Cellulomonas marina* FaRel, *B. subtilis* la1a PhRel2, *Coprobacillus* sp. D7 FaRel2, *Mycobacterium* phage Phrann PhRel (Gp29), and *Mycobacterium tuberculosis* AB308 CapRel (Jimmy et al., 2020). All of these SAS enzymes have proven to be highly toxic. Similarly, to Tas1, the toxicity of FaRel was shown to be mediated by production of adenosine analogue (p)ppApp, leading to inhibition of translation, transcription and replication (Jimmy et al., 2020).

2.2.3. toxSAS FaRel2, PhRel, PhRel2 and CapRel: growth inhibition by tRNA CCA end pyrophosphorylation

While analysing the nucleotide pool of *E. coli* with expressing toxSAS FaRel2, PhRel, PhRel2 and CapRel families we detected no accumulation of neither (pp)pApp or (p)ppGpp (Kurata et al., 2021; Kurata et al., 2022). This suggested that these toxSAS have a mechanism of toxicity profoundly different from that of FaRel and Tas1. Indeed, when I have performed metabolic labelling assays, I discovered that these toxSAS specifically inhibit protein synthesis (Kurata et al., 2021; Kurata et al., 2022).

Protein synthesis inhibition is a common mechanism of action amongst unrelated TA systems (Harms et al., 2018; Jurenas et al., 2022). A common target of translation-inhibiting TAs is transport tRNA, tRNA, which can be inactivated via cleavage (as exemplified by VapC toxins (Cruz, 2015)), acetylation of amino acid attached to tRNA 3'CCA (as exemplified by GNAT toxins such as AtaT (Jurenas et al., 2017)), or inactivation of the 3'CCA end through the addition of pyrimidines (as exemplified by MenT3 toxin (Cai, 2020)). Through a comprehensive set of experiments, we have established that by translation-inhibiting toxSAS such as FaRel2 inhibit aminoacylation of tRNA via tRNA 3'CCA end pyrophosphorylation, yielding aminoacylation-incompetent PP-tRNA (**Figure 7**) (Kurata et al., 2021).




Figure 8. SYNTH substrate specificity of RSHs. (A) Housekeeping RSHs synthesize (p)ppGpp by transferring the pyrophosphate group of ATP onto the ribose of either GDP or GTP and degrade the alarmone by hydrolysing the nucleotide back to GDP or GTP. (B) Secretion system effector Tas1 and toxSAS FaRel to produce toxic (pp)pApp alarmones. (C) Representatives of the majority of toxSAS subfamilies specifically inhibit protein synthesis by transferring the pyrophosphate group of ATP onto the 3' ribose position tRNA's CCA end, producing PP-tRNA. Adopted from (T. Kurata et al., 2021).

2.3. Small Alarmone Hydrolases (SAH)

Bacterial Small Alarmone Hydrolases (SAH) are a diverse and widespread (Atkinson et al., 2011) – but relatively poorly characterised group of single domain RSHs. By analogy to long HD-competent RSHs SpoT and Rel, the hydrolytic activities of SAH were initially believed to be limited to hydrolysis of (p)ppGpp. When the only human SAH representative – MESH1 – was discovered, it was suggested that it acts to (p)ppGpp, despite the lack of evidence of the alarmone present in metazoa (Sun et al., 2010).

In parallel with the discovery of SYNTH-competent RSHs being able to synthesise (pp)pApp (Ahmad et al., 2019; Jimmy et al., 2020) and PP-tRNA (Kurata et al., 2021), researchers started probing potential other catalytic activities of SAH. *Cellulomonas marina* SAH antitoxin protein (ATfaRel) was shown to neutralise the toxic effect of (p)ppApp-producing (Jimmy et al., 2020) and PP-tRNA producing toxSAS (Kurata et al., 2021), same detoxifying effects were

observed for human MESH1 (Kurata et al., 2021). SAH from *Methylobacterium extorquens* (Ruwe et al., 2018) and *Pseudomonas aeruginosa* (Steinchen et al., 2021) were shown to have a hydrolase substrate preference towards (p)ppApp over (p)ppGpp. It has been proposed that MESH1 could also degrade NADPH to NADH (Ding, 2020). However, follow up studies did not support this claim (Potrykus et al., 2020), and the native substrate of MESH1 in metazoan remains unclear.

3. Toxin-antitoxin (TA) systems

First representatives of toxin-antitoxin (TA) systems were discovered in the early 80s (Gerdes et al., 1986; Ogura and Hiraga, 1983). The classical TA systems are bicistronic – i.e. comprised of two gene – operons, in which one gene encodes a protein toxin and the other encodes a protein or RNA antitoxin which neutralises the toxin, either directly or indirectly. Studies of TA systems have exploded in the last years, with numerous new TA families being discovered, their mechanisms of action being characterised, biological functions established and possible applications for biotechnology put forward. In the following sections I will cover classification of functional types of TAs, provide an overview of the mechanisms of toxicity used by different TAs, discuss the specificity and promiscuity of toxin neutralisation by class II (i.e. protein toxin neutralised by protein antitoxin) TA systems, and, finally, touch upon the emerging understanding of cellular TA functions, with a special focus on phage defence via abortive infection (Abi).

3.1. Classification of TA systems

In the recent years many new TA systems were discovered, and a classification of TAs into eight classes (I–VIII) was formulated (**Figure 9**) (Jurenas et al., 2022). Exceptions to the classical bicistronic architecture with protein toxin have been identified. While in classical TAs the two genes forming an operon, type I and type VIII systems are not organised as a single operon. While almost type I–VIII toxins are proteins, the newly discovered VIII type toxins are RNAs (Choi, 2018; Li, 2021). Below I will describe the eight classes of TA systems and give examples of these systems.

Class I TA systems are comprised of a protein-based toxin and antisense RNA-antitoxin which prevents toxin that ‘masks’ the Shine-Dalgarno (SD) element of the of the toxin-encoding mRNA and prevents its translation (Darfeuille, 2007; Fozo, 2008; Gerdes, 1988). Type II TAs – which are the focus of my research presented in this thesis – are made up of two protein-encoding genes transcribed as an operon, with the toxin being neutralised by the antitoxin through formation of an inert complex (Jurenas et al., 2019; Li, 2009; Tam, 1989). Type III TAs are comprised of a toxic protein and an antitoxin RNA that inhibits the protein toxin by forming a non-toxic RNA-protein complex (Fineran, 2009; Samson, 2013).




Figure 9. Classification of Toxin-Antitoxin systems. (A) Type I systems are composed of RNA antitoxin that binds toxin-encoding mRNA, thus repressing the protein toxin expression. (B) Type II systems are composed of protein antitoxin that directly binds and inhibits toxin protein. (C) Type III systems are composed of RNA antitoxins that bind and inhibit protein toxin. (D) Type IV systems have protein antitoxins that protect the toxin targets from toxin activity. (E) The type V system has an endoribonuclease antitoxin that degrades the transcript of the toxin. (F) The type VI system include an antitoxin protein that acts as an adaptor targeting the toxin for activation protease for degradation. (G) Type VII systems encode protein antitoxins that inactivate the toxin through post-translational modification. (H) Type VIII systems use RNA antitoxins that act as transcriptional repressors of expression of RNA toxin. Toxins are shown in red, antitoxins are shown in blue. Adopted form (Jurenas et al., 2022).

Type IV is comprised of proteinaceous toxin and antitoxin with the toxic effects being counteracted via antitoxin-mediated modification of toxin's cellular targets (Jankevicius et al., 2016; Jimmy et al., 2020; Masuda et al., 2012). Type V is comprised of an RNase antitoxin which degrades the toxin-coding mRNA (Jurenas et al., 2022). In Type VI proteinaceous antitoxin counteracts the proteinaceous toxin by acting like adaptor for ATP dependent proteases which specifically degrade the protein toxin (Aakre et al., 2013). The VII class is similar to VI, but instead of acting via toxin degradation, inactivation of the toxin is mediated by its posttranslational modification (Songailiene, 2020; Yu, 2020). Finally, the most recent type to be discovered is type VIII type, which is unique in containing an RNA toxin (Choi, 2018; Li, 2021). In type VIII an RNA antitoxin represses the expression of toxic RNA by acting as antisense or by acting as a Cas-dependent transcriptional repressor.

Finally, some toxins are neutralised by two synergistically acting antitoxins acting as class II and class IV. One example is FaRel toxSAS which is neutralised by a class II antitoxin that forms a binary complexed with FaRel and a class IV SAH antitoxin that neutralises FaRel by degrading the toxic alarmone (p)ppApp (Jimmy et al., 2020). In the following chapters I will focus on type II TAs since these systems were the focus of my research.

3.2. Molecular mechanisms of controlled growth inhibition employed by TA systems

Toxic effectors act on a variety of cellular targets, with several aspects of bacterial physiology being targeted more commonly than the others (**Figure 10**). Below I will describe most common growth inhibition strategies employed by TA toxins.

Many TA toxins target replication either by damaging DNA directly or compromising replication machinery (Aakre et al., 2013; Jankevicius et al., 2016; Jurenas et al., 2022). One of such TAs is chromosomally encoded type IV DarTG system, with the DarT toxin catalysing ADP-ribosylation of thymine residues in single stranded DNA (ssDNA). This modification leads to compromised DNA replication and induction of SOS DNA damage response. The antitoxin DarG neutralizes the toxin's activity by glycohydrolisation of ADP-ribose (ADPr) moiety, thus removing the modification from thymine residues (Jankevicius et al., 2016). SocB VI type toxin of the SocAB TA system interrupts the replication elongation by direct binding to DnaN, resulting in the replication fork collapse, and, similarly to DarT, this toxic effect also induces the SOS response (Aakre et al., 2013). ATP-dependent proteases ClpX and ClpP (ClpXP) are essential for neutralisation of SocB toxin (LeRoux, 2022; Texier, 2021), since SocA acts as a proteolytic adaptor antitoxin which helps ClpXP to degrade the SocB. Two more examples of toxin-antitoxin systems that inhibit replication are CcdB and ParE (toxic effectors of type II TAs CcdA/CcdB and ParD, respectively) which inhibit replication by binding to DNA gyrase (Yuan J., 2010).




Figure 10. Diversity of molecular targets of toxic effectors of TA systems. (A) DNA is directly targeted by the DNase RalR and the ADP-ribosyltransferase DarT. The replication machinery is targeted by SocB which binds to the β -sliding clamp subunit of DNA polymerase III. DNA gyrase is inhibited by direct binding of CcdB. (B) Translation is targeted by a numerous toxins acting at every level of protein synthesis: toxSAS inhibit tRNA aminoacylation by pyrophosphorylation of the 3' ribose position tRNA's CCA end. AtaT toxins acetylate the amino acid residue of charged tRNAs. Doc phosphorylates elongation factor Tu (EF-Tu) and prevents the aminoacyl-tRNA delivery. MazF RNase toxins degrade free mRNAs and ribosomal RNAs. RelE RNase toxins cleave mRNA in the ribosomal A site. (C) TisB, HokB and GhoT are small peptides that form pores in the inner membrane to compromise its integrity. (D) ToxSAS toxins synthesizing the alarmone (p)ppApp to the drop cellular levels of GTP and ATP. The MbcT toxin degrades NAD⁺. Adapted from (Jurenas et al., 2022).

Another important target of TA toxins is translational machinery (Jurenas et al., 2022). Most of the toxins targeting translation are RNases (Harms et al., 2018; Jurenas et al., 2017). A classical example is RelE toxin of the RelBE type II system – a ribosome-depended enzyme that cleaves the mRNA in the ribosomal A site (Pedersen K., 2003). Another example is MazF of the MasEF system which degrades free RNAs such as mRNA and rRNA precursors (Culviner, 2018; Mets, 2017). GNAT domain-containing toxins inactivate aminoacyl-tRNAs by

acetylation of the amino acid moiety, with prime examples being AtaT toxin of the AtaR-AtaT system, that specifically modifies initiator fMet-tRNA^{fMet} (Cheverton A. M., 2016; Jurenas et al., 2017). The HipA toxin phosphorylates aminoacyl-tRNA synthetases to inhibit tRNA charging (i.e. aminoacylation) (Kaspy et al., 2013). Finally, as it was demonstrated in our laboratory, many of toxSAS toxins pyrophosphorylate 3' CCA end of deacylated tRNA thus precluding its charging with amino acids (Jimmy et al., 2020; Kurata et al., 2021).

The third major TA target is cell envelope, which is targeted by many type I TA toxins. A classic example is type I HokB toxin which causes membrane depolarization and disrupts the proton motive force upon insertion into the inner membrane. Type V GhoT toxin also induces cell lysis, with GhoS antitoxin rescuing the cell by digesting *ghoT* transcripts (Wang et al., 2012).

Finally, several TA toxins abrogate the growth by inducing an acute metabolic stress by either producing toxic small metabolites or degrading essential house-keeping metabolites. Toxicity of FaRel toxSAS is mediated by production of alarmone nucleotide (p)ppApp (Jimmy et al., 2020). Type II MbcT toxin which depletes NAD⁺ a central electron carrier essential for redox reactions (Freire, 2019).

3.3. Specificity and promiscuity of toxin neutralization amongst class II TA systems

Bacterial species encode numerous TA systems in their genomes, and often bacteria encode several paralogous TAs that are similar at sequence and levels (Leplae et al., 2011). However, naturally occurring paralogues of TA systems do not exhibit cross-talk, i.e. antitoxins are specific for cognate toxins and do not cross-neutralise non-cognate toxins (Aakre et al., 2015). However, through directed evolution – i.e. by applying rounds of selection to mutagenized libraries expressing variants of antitoxins – is possible to change neutralisation specificity, as shown for ParD-ParE TA proteins (Aakre et al., 2015). Furthermore, through addition selection rounds it is possible to narrow the specificity spectrum, so that the evolved antitoxin cannot neutralise the original cognate toxin (Aakre et al., 2015). This evolutionary plasticity of TA pairs is referred to promiscuity (**Figure 11A**). A more extreme case of antitoxin promiscuity regarding neutralised toxins – hyperpromiscuity – is provided by members the Panacea (PanA) antitoxin family (Kurata et al., 2022). In this case, members of Panacea-containing antitoxins can neutralise diverse toxins that do not share either common fold or sequence homology (**Figure 11B**).




Figure 11. Antitoxin promiscuity and hyperpromiscuity. (A) A promiscuous antitoxin has relaxed neutralization specificity toward its target toxin and can neutralize a range of related toxins which all share the same structural fold. (B) A hyperpromiscuous antitoxin domain, as exemplified by Panacea, can evolve to neutralize unrelated toxins that do not share neither structural fold nor mechanism of toxic action (Kurata et al., 2022).

3.4. Biological functions of TA systems

The first biological function of TA systems to be discovered is the F plasmid addiction mediated by CcdAB TA pair (Gerdes et al., 1986; Ogura and Hiraga, 1983) (Figure 12). Plasmid addiction mediated by so-called post segregational killing (PSK) is a result of an interplay between a short-lived proteolytically unstable antitoxin combined with proteolytically stable toxin (Jensen and Gerdes, 1995; Van Melderen et al., 1994). If the bacterium loses the TA-encoding plasmid, the antitoxin is degraded over time, resulting in free toxin which, in turn, kills the cell. By eliminating the cells that have lost the plasmid from the population, PSK causes bacterial ‘addiction’ to the TA-encoding plasmid. In addition to CcdAB, other PSK loci include Hok/Sok system and Kis/Kid system encoded on plasmid R1, as well as ParDE system encoded on plasmid RK2 (Roberts, 1994; Tsuchimoto, 1988).

The next biological function of TA systems to be proposed is their role as metabolic ‘breaks’ that are engaged upon stress (Christensen and Gerdes, 2003; Ronneau, 2019). However, this stress response function of TAs is a matter of controversy. It was shown that while different stresses do induce the transcriptional activation of type II TA systems in *E. coli*, this does not result in generation of free toxins that would, in turn, repress the growth and throttle the metabolism (LeRoux, 2020). Antibiotic challenge is one type of stress, and one of the mechanisms how bacteria survive this stress is formation of a small sub-population antibiotic tolerant bacteria within a genetically identical population – formation of so-called persisters cells (Kaldalu N., 2020). High levels of persistence were detected in an *E. coli* strain that carried a mutation in the *hipAB* TA system, the

so-called *hipA7* allele (*hip* stands for ‘high incidence of persistence’) (Korch et al., 2003). This observation suggested that TAs could act as the drivers of persistence. However, knockout of *hipAB* locus does not have effect on the persister frequency (Korch et al., 2003). The Kenn Gerdes lab pursued this direction further and created an *E. coli* strain in which ten TA loci were genetically ablated, the $\Delta 10$ TA *E. coli* – and, indeed, this strain appeared to have much lower persistence levels, seemingly supporting the key role of TAs as the drivers of persistence (al., 2018; Maisonneuve and Gerdes, 2014). However, later it has been discovered that the $\Delta 10$ strain (and several related strains lacking TA modules) were infected with $\Phi 80$ and λ bacteriophages, which explained the phenotype (Goormaghtigh et al., 2018; Harms et al., 2017). Currently the possible role of TAs in persistence is unclear.




Figure 12. Biological functions of TAs. Three major categories of proposed functions for TA systems are (A) plasmid maintenance, (B) stress response and (C) phage defence. (A) Loss of a TA-encoding plasmid can lead to degradation of the antitoxin, leading to free toxin in the cell, which then prevents growth of a cell that is lacking the plasmid. This ensures cellular addiction to the TA-encoding plasmid. (B) In response to abiotic stress antitoxins can be degraded which leads to transcriptional induction of TA modules. This can lead to TA-mediated toxicity slowing down bacterial growth and promoting stress tolerance. (C) For some TA systems, phage infection was shown lead to release of active toxin. This results in infected cell effectively committing suicide and limiting the phage spread in bacterial population. Adapted from (LeRoux, 2022).

Finally, the function that gained a lot of attention in the recent years is the role of TAs as inducible toxic effectors that mediate anti-phage defence via abortive infection (Abi) mechanisms (LeRoux, 2022; Lopatina, 2020; Maikova, 2018). TA-mediated Abi relies on bacterial cell sensing the invading phage, activating the TA-mediated cytotoxicity and ‘committing suicide’ in order to halt the phage spread through bacterial population (LeRoux, 2022; Wein, 2022). The first TA system that was suggested to act as an anti-phage system is the Type II RnlAB system with RnlA RNase effector toxin degrading phage (and host) RNA in response to infection (Otsuka, 2005). Similarly, to RnlAB, type III ToxIN abortive infection TA system acts via release of the toxN RNase (Guegler and Laub, 2021). It was shown that mycobacterial prophage Phrann that encodes a gp29:gp30 toxSAS TA pair renders its bacterial host resistant from co-infection by other temperate phages such as Tweety, suggesting that toxSAS TAs could act as phage defence systems (Dedrick et al., 2017). Recent experiments with CapRel^{SJ46} toxSAS system have directly established the role of this TA in phage defence by demonstrating that this fused TA (i.e. a TA in which toxin and antitoxin constitute one polypeptide) directly binds phage major capsid protein, which, in turn, results in toxSAS activation and abortive infection (Zhang et al., 2022).

AIMS OF THE STUDY

My PhD studies focused on several mechanisms employed to suppress cellular metabolism, with a specific focus on translation inhibition by toxins and ribosome hibernation factors. Specifically, the aims were:

- To uncover the mechanisms of toxSAS-mediated growth inhibition (Paper I)
- To uncover the mechanisms of PanT-mediated growth inhibition (Paper II)
- To exploit the genetic ablation of ribosome inhibition through dimerization in order to develop more active lysate-based bacterial and yeast *in vitro* translation systems (Paper III)

MATERIALS AND METHODS

All materials and methods are described in publications I, II and III. The most important methods are specified below.

1. Toxicity neutralization assay

Toxicity neutralization assays were performed in papers I and II.

LA plate with 1% glucose and 25 µg/ml chloramphenicol and 100 µg/ml carbenicillin containing *E. coli* BW25113 with toxin plasmid and/or antitoxin plasmid and plates with empty vector plasmid control (pBAD33 for toxin and pKK223-3 for antitoxin) were grown overnight at 37 °C.

Next day a single colony was inoculated into 2 ml of LB medium contain 100 µg/ml carbenicillin, 25 µg/ml chloramphenicol and 1% glucose. The cultures were incubated in the liquid Luria Broth (LB) medium at 37 °C for 16 hours at 180 rpm.

Next, the overnight culture was diluted to an OD₆₀₀ of 1.0 with LB medium. 90 µl of LB medium was added into wells of sterile 96-well Falcon plate. Bacterial cultures were diluted serially (10⁻¹ to 10⁻⁸-fold) by taking 10 µl from the well on the immediate left and transferring it to the next well (pipette tips was changed between dilutions). 5 µl of the dilutions were spotted onto desired non-induction (1% glucose and 25 mg/ml chloramphenicol and 100 mg/ml carbenicillin) and induction plates (0,2% arabinose, 1mM IPTG and 25 µg/ml chloramphenicol and 100 µg/ml carbenicillin) using a multi-channel pipette. Plates were incubated at 37 °C for 23 hours. The results were recorded by counting CFU or making pictures of the plates.

2. Metabolic labelling

Metabolic labelling assays were performed in papers I and II.

BW25113 *E. coli* wild-type strain carrying pKK223-3 and toxin plasmid was streaked on LA plate supplemented with 1% glucose, 25 µg/ml chloramphenicol and 100 µg/ml carbenicillin.

Three colonies were used to inoculate individual tubes containing 2 ml of MOPS liquid medium with 1% glucose, 25 µg/ml chloramphenicol and 100 µg/ml carbenicillin. The tubes were incubated with shaking (180 rpm) at 37 °C overnight (16–18 hours).

Next day the overnight precultures were diluted to OD₆₀₀ of 0.05 in 15 ml MOPS liquid medium with 0.5% glycerol supplemented with 19 AA at final concentration 25 µg/ml (methionine excluded from the medium) plus 25 µg/ml chloramphenicol and 100 µg/ml carbenicillin. The culture was grown at 37 °C, 200 rpm until OD₆₀₀ of 0.2–0.3.

While the culture was growing, 10 μl of 4.3 μCi ^{35}S -methionine, 0.65 μCi ^3H -uridine or 2 μCi ^3H -thymidine were added into autoclaved 1.5 ml tubes, kept on ice or at 4 $^{\circ}\text{C}$ in the fridge. Separately 200 μl aliquots of 50% TCA were prepared in 1.5 ml Eppendorf tubes and kept on ice or at 4 $^{\circ}\text{C}$. Tubes with isotopes were prewarmed at 37 $^{\circ}\text{C}$ for 10 minutes before metabolic labelling.

When OD_{600} of the bacterial culture reached to 0.2–0.3, 1ml of culture was transferred into prewarmed tube containing isotope solution and kept at 37 $^{\circ}\text{C}$ for 8 minutes. Immediately after that 20% of arabinose was added at final concentration 0.2%. Time points were taken after 2, 5, 10, 15 minutes. In parallel, the OD_{600} of the culture was measured. The labelled solution was added to ice cold 1.5 ml tube containing 200 μl of 50% TCA. The mixtures were kept on ice.

After that filtration system was set up. The GF/C filter was in the beginning washed with 1–2 ml of 5% TCA. Later TCA-stopped bacterial culture was added and washed 2 times with 5 ml of pre-chilled 5% TCA, and 2 times with 5 ml of pre-chilled 95% ethanol. The filters were put into scintillation vials and dried for at least two hours or overnight at room temperature. After this 5 ml of scintillation cocktail was added to the vials. The vials were put on the orbital shaker for 15 minutes at room temperature and then subjected to scintillation counting using TRI-CARB 4910TR 100 V scintillation counter (PerkinElmer).

3. *In vitro* transcription-translation assays

Transcription-translation assays using cell-free lysates were performed in paper III.

3.1. Preparation of cell-free translational extracts

Cell-free translational lysates were prepared in paper III.

The *Bacillus subtilis* 168 WT and Δhpf mutant were plated on LA plate without antibiotics. Overnight cultures were started by inoculation single colony into 50 ml liquid LB. The culture was grown for 16 hours, at 37 $^{\circ}\text{C}$, 180 rpm. Next day, the preculture was diluted to OD_{600} of 0.05 in 800 ml of LB. The cells grew at 37 $^{\circ}\text{C}$, 180 rpm for 5 hours to OD_{600} 1.8–2.2. Bacterial cells were collected by centrifugation at 10 000g for 3 minutes at 4 $^{\circ}\text{C}$ in a Beckman JLA-10.500 rotor. The cell pellets were washed twice with 100 ml and 50 ml of ice-cold 1x 12S lysis buffer (10 mM Tris-acetate pH 8.2, 60 mM $\text{C}_5\text{H}_8\text{KNO}_4$, 14 mM $\text{Mg}(\text{C}_2\text{H}_3\text{O}_2)_2$, 0.5 mM PMSF, 1 mM DTT). After each washing step cells were pelleted by centrifugation at 10 000 g for 3 minutes at 4 $^{\circ}\text{C}$ in a Beckman JLA-10.500 rotor. The final centrifugation was done in 50 ml Falcon tubes at 3220 g for 30 minutes at 4 $^{\circ}\text{C}$ (Eppendorf Centrifuge 5810/5810 R). The cells were weighted using Delta Range balance Mettler, PM4600 (4–5 g was usually obtained). At this step cells can be zip-frozen in liquid nitrogen and stored at -80 $^{\circ}\text{C}$ until further use. After that cell pellets were resuspended in 12 ml of 1x12S lysis buffer and lysed by Pressure Cell/Homogenizer at 1.5 bar, 1 pass.

The cell debris was pelleted at 16 000 g for 10 minutes using Beckman JA-25.50 rotor. The supernatant was collected and desalted using 5 ml Zebra Spin Desalting Columns (ThermoFisher) and equilibrated with 1x 12S lysis buffer. The OD₂₆₀ was measured, and lysates were diluted if needed to equal optical density.

The *Saccharomyces cerevisiae* MBS and MJY1079 strains were plated on YPD agar plate without antibiotics. Overnight cultures were started by inoculation of a single colony into 50 ml of YPD liquid medium and incubated at 30 °C, 140 rpm for 24 hours. Next day, preculture were diluted to OD₆₀₀ of 0.001 in 800 ml of YPD. The cells grew at 30 °C, 140 rpm for 12–18 hours to an OD₆₀₀ of 4–7. After that the cells were harvested by centrifugation at 7000 g for 10 minutes at 4 °C in a Beckman JLA-10.500 rotor. The pellets were washed twice with 1x Sarnow A buffer (30 mM HEPES pH 7.6, 100 mM KCH₃COO, 2 mM Mg(C₂H₃O₂)₂, 0.5 mM PMSF, 1 mM DTT). Cell pellets were centrifuged under the same condition after each washing step with 100 ml and 50 ml of ice-cold buffer. The final centrifugation was done in 50 ml Falcon tubes with 20 ml of 1x Sarnow A buffer at 3220g for 30 minutes at 4 °C (Eppendorf Centrifuge 5810/5810 R). At this step cells can be zip-frozen in liquid nitrogen and stored at –80 °C until further use. After that cell pellets were resuspended in 1/10 volume (w/v) of 1x Sarnow A buffer. The yeast pellets were lysed in liquid nitrogen in mortar for 20 minutes. The obtained lysates were collected in 50 ml Falcon tubes and left on ice for 5 hours to melt. The cell debris was removed by centrifugation at 4000 g for 30 minutes at 4 °C (Eppendorf Centrifuge 5810/5810 R). The supernatant was transferred to new Eppendorf tubes and centrifuged at 21 000 g for 10 minutes at 4 °C (Heraeus Fresco 21 Microcentrifuge, ThermoFisher). The supernatant was desalted with 5 ml Zebra Spin Desalting Columns (ThermoFisher). The lysates were aliquoted and quickly frozen in liquid nitrogen and stored at –80 °C.

3.2. Cell-free transcription-translation reactions and luciferase assay

For *B. subtilis* lysates the total volume of a reaction was 30 µl, which included 50% v/v of lysate and 50% v/v of buffer. The final reaction conditions were: 5–15 mM Mg(C₂H₃O₂)₂, 2 mM of each amino acid (excluding methionine), 60 mM HEPES pH 8.2, 4.8 mM ATP, 3.4 mM GTP, CTP and UTP, 0.068 mM folinic acid, 36% (w/v) PEG-8000, 60 mM glucose, 2 µg/ml plasmid pIVEX2.3MCs FFluc, 2 mM DTT, 1 mg/ml T7 RNAP, 20 mM K₂HPO₄ pH 7.22, 90 mM K-glutamate, 80 mM NH₄CH₃CO₂. The total volume (30 µl) of the cell-free reaction was aliquoted into 1.5 ml Eppendorf Safe-Lock Tubes. The lysates were mixed well by pipetting and incubated at 37 °C on Eppendorf Thermomixer with shaking (500 rpm) for 1 hour.

For *S. cerevisiae* lysates, the total volume of the reaction was 30 µl as well (50% v/v of lysate and 50% v/v of buffer). The final reaction conditions were: 1–3 mM Mg(C₂H₃O₂)₂, 0,025 mM each amino acid (excluding methionine),

1 mM 20x S-J buffer (200 mM HEPES pH 7.4, 2M KCH₃COO, 20 mM DTT), 3 mM ATP, 0.25 mM GTP, 25 M phosphocreatine, 0.3 μ/μl rRNasin, 0.04 mg/ml creatine phosphokinase, 0.005 mg/ml capped T7-FFLuc-A30 mRNA. Before using the mRNA, it was unfolded at 70 °C for 7 minutes and refolded by cooling on ice. The cell-free reaction mixture was aliquoted into 1.5 ml Eppendorf Safe-Lock Tubes, mixed well by pipetting and incubated at 25 °C on Eppendorf Thermomixer with shaking (500 rpm) for 30 or 60 minutes.

Luciferase Assay was used for both bacterial and yeast lysates to determine the influence of ribosome dimerization on the translation process. A Steady-Glo Luciferase Assay (Promega) was conducted following the manufacturer's instructions. Luciferase assay reagent was aliquoted (50 μl) into 1.5 ml Eppendorf tubes and kept in the dark at room temperature. Then, 10 μl of translation reaction was added and luminescence recorded immediately using a GloMax 20/20 Luminometer (Lus-0-Inj Promega program).

RESULTS AND DISCUSSION

I. toxSAS FaRel2, PhRel, PhRel2 and CapRel pyrophosphorylate tRNA CCA end to abrogate the tRNA aminoacylation (Paper I)

Out of the five subfamilies of toxSAS enzymes which act as toxic effectors of TA modules, the mechanism of toxicity of only one – the (p)ppApp-producing FaRel – was characterised in detail in the original report (Jimmy et al., 2020). Therefore, I have set out to uncover the molecular mechanism of toxicity of the four unexplored toxSAS representatives: PhRel2 identified in *Bacillus subtilis* la1a, FaRel2 identified in *Coprobacillus* sp. D7, PhRel (Gp29) identified in *Mycobacterium* phage Phrann and CapRel identified in *Mycobacterium tuberculosis* AB308.

First, I performed the HPLC analysis of bacterial nucleotide pools (Varik et al., 2017). Surprisingly, expression of none of the TA systems under study produced (p)ppGpp or (pp)pApp nucleotides, indicating that their mechanism of toxicity is profoundly different from that of FaRel (**Figure 13A**).




Figure 13. Inhibition of protein synthesis is an evolutionary widespread mechanism of toxSAS-mediated growth arrest. (A) The expression of *B. subtilis* la1a PhRel2 does not perturb the adenosine nucleotide pools, and (pp)pApp is not detectable upon expression of the toxin. (B-F) Metabolic labelling assays following incorporation of ³⁵S-methionine (black traces), ³H-uridine (red traces), and ³H-thymidine (blue traces). Expression of *B. subtilis* la1a PhRel2 (B), *Coprobacillus* sp. D7 FaRel2 (C), *P. aeruginosa* Tas1 SS effector (D), *M. tuberculosis* AB308 CapRel (E) and *Mycobacterium* phage Phrann PhRel Gp29 (F) from the pBAD33-based constructs was induced with 0.2% L-arabinose. Adapted from (Kurata et al., 2021).

Next, I used metabolic labelling approach to uncover which of the biosynthetic processes is inhibited by toxSASs (Jimmy et al., 2020). I followed the incorporation of ^{35}S methionine into proteins, ^3H uridine into RNA and ^3H thymidine into DNA. In stark contrast to FaRel (Jimmy et al., 2020) – and (pp)pApp-producing Tas1 (**Figure 13D**) – the rest of toxSAS inhibit translation, as signified by compromised ^{35}S methionine incorporation (**Figure 13**).

The next question we asked was as to how the translation-targeting toxSAS inhibit protein synthesis on molecular level. The hypothesis was that just as FaRel could switch its substrate specificity from recognising adenosine to guanosine in NT/DPs, the translation-targeting toxSAS could further change their substrate specificity and recognise the A residue of tRNA CCA end instead of that of free AT/DP nucleotide. This turned out to be exactly the case. We could detect that when radioactive ATP was present then FaRel2 was incubated with initiator tRNA_i^{fMet} and ^{32}P -labelled ATP (**Figure 14B**).




Figure 14. *Coprobacillus* sp. D7 FaRel2 pyrophosphorylates the tRNA 3'CCA end to inhibit tRNA aminoacylation. A reconstituted ^{32}P transfer reaction using 50 nM FaRel2, 100 μM γ - ^{32}P -ATP, and either 5 μM tRNA_i^{fMet} or 5 μM tRNA^{Phe} as a substrate. ^{32}P transfer was either quantified via scintillation counting (**A**) or visualised using a Phosphorimager (**B**). Adapted from (Kurata et al., 2021).

Final validation of the chemical nature of CCA modification installed by toxSAS came from the lab of our collaborator, Tsutomu Suzuki. Using LC-MS system to analyse the RNA fragments generated from 3' terminal regions of tRNA CCA, the Suzuki lab directly established that the 3'CCA end of tRNA is pyrophosphorylated by *Coprobacillus* sp. FaRel2 (see (Kurata et al., 2021) for detail).

Next, I tested if the cellular toxicity of tRNA-modifying FaRel2 could be neutralized by SAH enzymes: human SAH enzyme Mesh1 and *C. marina* ATfaRel (**Figure 15**). After co-expression of human MESH1 or *C. marina* ATfaRel counteracted the growth inhibition by FaRel2, albite did not fully. This indicates that the SAH tested can convert pyrophosphorylated tRNA back to deacylated tRNA, i.e., catalyse RNA modification – a type of reaction that was never reported for SAH before. Complementary biochemical experiments using ^{32}P -labelled tRNA-PP and SAH that performed by my co-author Tatsuaki Kurata directly supported my microbiological experiments (see (Kurata et al., 2021) for detail).




Figure 15. Co-expression of SAH enzymes *C. marina* ATfaRel and *H. sapiens* MESH1 counteracts FaRel2-mediated toxicity. Co-expression of either human MESH1 or *C. marina* ATfaRel SAH enzymes counteracts the toxicity of *Coprobacillus* sp. D7 FaRel2 tRNA-modifying toxSAS. The SAH enzymes and FaRel2 toxSAS were expressed from pMG25 and pMR33 derivative plasmids, respectively. Adapted from (Kurata et al., 2021).

Inhibition of translation through modification of tRNA is a recurring theme in TA-mediated toxicity, with notable examples being GCN5-related N-acetyl-transferase (GNAT)-like toxins AtaT (Cheverton A. M., 2016; Jurenas et al., 2017), VapC PIN-like domain nucleases (Gobert et al., 2019; Winther and Gerdes, 2011) and DUF1814-family nucleotidyltransferase-like toxins MenT1 adding pyrimidines (C or U) to tRNA 3'CCA end (Cai, 2020). Our discovery adds one more example to this common theme. It also rises the question as to why amongst the three steps of the central dogma – translation, transcription, replication – it is the translation that is commonly targeted by TAs. To the best of my knowledge no TAs targeting transcription has been identified to date.

II. Panacea: a hyperpromiscuous antitoxin protein domain involved in neutralization of diverse toxin domains (Paper II)

FlaGs-guided bioinformatic analysis (Saha et al., 2021) of the antitoxin that neutralises *B. subtilis* Ia1a PhRel2 toxSAS uncovered that i) the antitoxin contains a domain of unknown function (DUF) DUF4065 ii) DUF4065 is found in TA-like arrangements with numerous unrelated toxins (Kurata et al., 2022). New TA pairs with DUF4065-containing antitoxins were found to be widely distributed in bacteria, archaea and bacteriophages. Given the wide distribution DUF4065 and its ability to neutralise unrelated toxins, we renamed it to Panacea after Greek goddess of universal remedy, with Panacea-containing toxins referred to as PanA's and their toxins as PanT's.

The toxins in these pairs were predicted to be mRNA interferases (RNases) (Christensen and Gerdes, 2003; Yamaguchi et al., 2009), members of Fic/Doc toxin family (Castro-Roa, 2013), membrane disruptors (Verstraeten et al., 2015), enzymes involved in nucleotide modification (Bordes, 2011) and toxSASs (Jimmy et al., 2020) (**Figure 16A**). For experimental validation of PanTAs systems in neutralization assays were selected nine TA pairs that are sampling all of these diverse predicted mechanisms of toxicity (**Figure 16B**).




Figure 16. PanA antitoxins neutralise evolutionarily diverse TA toxins. (A) The maximum likelihood tree of PanA sequences, annotated with conserved gene neighborhoods generated with FlaGs. **(B)** Validation of panAT TA pairs by toxicity neutralization assays. Overnight cultures of *E. coli* strains transformed with pBAD33 and pKK223-3 vectors or derivatives expressing putative *panT* toxins and *panA* antitoxins, correspondingly, were adjusted to OD₆₀₀ 1.0, serially diluted, and spotted on LB medium supplemented with appropriate antibiotics and inducers (0.2% arabinose for *panT* induction and 1 mM IPTG for *panA* induction). Adapted from (Kurata et al., 2022).

To uncover the mode of action of PanTs, I used the metabolic labelling assay which was already described in the previous chapter (Paper I, (Kurata et al., 2021)).

As expected for predicted translation inhibitors, toxSASs *L. animalis* PhRel2_{Lac.ani.} and toxSAS *V. harveyi* CapRel_{Vib.har.}, RNases PanT_{Pse.mor.} as well as PanT_{Bif.rum.} and Fic/Doc toxin *C. doosanense* Fic/Doc_{Cor.doo.} all specifically inhibited incorporation of radiolabelled ³⁵S methionine, thus establishing translation as one of the primary targets of PanTs (**Figure 17**).




Figure 17. Protein synthesis is a major target of PanT toxins. Metabolic-labeling assays following the incorporation of ³⁵S methionine (black traces), ³H uridine (red), and ³H thymidine (blue) upon expression of translation-inhibiting PanT representatives: (A) *L. animalis* PhRel2 and (B) *V. harveyi* CapRel tox-SAS; putative RNases (C) PanT_{Bif. rum.} and (D) PanT_{Pse. mor.} and (E) *C. doosanense* Fic/Doc_{Cor. doo.} toxin. Expression of PanTs in *E. coli* BW25113 was induced with 0.2% L-arabinose. Adapted from (Kurata et al., 2022).

Next, I performed metabolic labelling with predicted membrane disrupting toxins. For this kind of toxins, one would expect that all the three probed metabolic processes – translation, transcription and replication – would be affected simultaneously and to the same extent. Results obtained with PanT_{Esc.col.} (Figure 18A), PanT_{Bar.api.} (Figure 18C), and PanT_{Hel.sp.} (Figure 18C) are in good agreement with this prediction. In the case of *E. coli* STEC PanT_{Esc.col.} toxin and *Helicobacter* sp. PanT_{Hel.sp.} (Figure 18A–C) abrogation of incorporation of radiolabelled precursors happens immediately after toxin induction. In the case of *B. apis* PanT_{Bar.api.} toxin the inhibition of replication, transcription and translation is more gradual, and at 15 min time point after induction of toxin the decrease in incorporation efficiency was over 80%.




Figure 18. Membrane-targeting PanT's simultaneously abrogate translation, transcription and replication. Metabolic labelling assays with wild-type *E. coli* BW25113 expressing (A) PanT_{Esc. col.}, (B) PanT_{Bar. api.} or (C) PanT_{Hel. sp.} PanT toxins. Adapted from (Kurata et al., 2022).

I have obtained rather unexpected results with *Burkholderia* prophage PanT_{Bur.phage} toxin that was predicted to be a nucleotide-modifying enzyme. Metabolic labelling data revealed that this toxin inhibits transcription, with weaker effects on translation and even weaker on replication (**Figure 19A**). HPLC-based analysis of nucleotide pools revealed that PanT_{Bur.phage} induction *E. coli* resulted in depletion of GTP and production of ppGpp (**Figure 19C**). One possibility is that the toxin itself produced (p)ppGpp, and the other is that it activates the alarmone production by RelA. To discriminate between these two possibilities, I have repeated the HPLC analysis using a *relA* knockout *E. coli* strain (**Figure 19B**). In this strain no accumulation of (p)ppGpp was detected, suggesting that PanT_{Bur.phage} activates RelA. To test if activation of RelA is crucial for PanT_{Bur.phage}-mediated toxicity, I assessed the growth inhibition PanT_{Bur.phage} as well as performed the metabolic labelling assays in a *relA* knockout *E. coli* strain (**Figure 19B**). Since PanT_{Bur.phage} inhibited the growth of this strain just as it did in the case of wild type and exhibited the same pattern in metabolic labelling assays, I concluded that activation of RelA-mediated stringent response is not crucial for PanT_{Bur.phage} mechanism of action.




Figure 19. Expression of PanT_{Bur.phage} toxin encoded in *Burkholderia* prophage phi52237 compromises transcription and translation and induces the RelA-mediated stringent response. (A and B) Metabolic labelling assays using either wild-type (A) or ΔrelA (B) *E. coli* BW25113 expressing PanT_{Bur.phage} toxin. (C and D) HPLC analysis of guanosine nucleotide pools in either wild-type (C) or ΔrelA (D) *E. coli* BW25113 expressing PanT_{Bur.phage} toxin. Cell cultures were grown in defined minimal MOPS medium supplemented with 0.5% glycerol at 37 °C with vigorous aeration. Expression of PanT_{Bur.phage} toxin was induced with 0.2% L-arabinose at the OD₆₀₀ 0.2. Intracellular nucleotides are expressed in pmol per OD₆₀₀×mL as per inset. Error bars indicate the SE of the arithmetic mean of three biological replicates. Adapted from (Kurata et al., 2022).

Finally, I performed cross-neutralization assay to test if non-cognate PanA can neutralize of non-cognate PanT (Figure 20A). The rationale for this experiment is that if PanAs can swap partners in the course of evolution, they might be intrinsically promiscuous, i.e. able to neutralise non-cognate toxins. However, the experiments revealed that PanAs are specific to cognate toxins, suggesting that promiscuity requires mutational adaptation of the PanA to its new PanT partners. Indeed, through directed evolution experiments, my college Toomas Mets could select evolved PanA_{Vib.har.} version that was able to neutralise non-cognate PanT PhRel2_{Bac.sub.} (Kurata et al., 2022).




Figure 20. PanA antitoxins are highly specific for cognate PanT toxins. Exhaustive cross-neutralization testing was used to probe the specificity of PanA antitoxins toward PanT toxins. The overnight cultures of *E. coli* strains transformed with pBAD33 and pKK223-3 vectors or derivatives there of expressing toxin and PanA antitoxins was adjusted to 1.0, cultures serially diluted from 10¹-to10⁶-fold and spotted on LB agar medium supplemented with appropriate antibiotics as well as inducers (0.2% arabinose for toxin induction and 1 mM IPTG for induction PanA variants); 10¹-fold dilution is shown. Adapted from (Kurata et al., 2022).

Our study brought the Panacea domain to the spotlight. Many questions remained unanswered by our initial study: is Panacea neutralising the toxins directly or does it merely serve as a scaffold, a platform, with Panacea-associated domains doing the job? Is Panacea unique – or are there other hyperpromiscuous antitoxin domains? Systematic application of FlaGs in an iterative mode can answer the latter question, and the former question requires structural studies. Prediction of PanTA structures by AlfaFold2 (Jumper et al., 2021; Jumper and Hassabis, 2022) can generate insights that can then be validated experimentally.

III. Elimination of ribosome inactivating factors improves the efficiency of protein production in yeast and *B. subtilis* in vitro translational lysates (Paper III)

Efficiency of lysate-based *in vitro* translation systems depends on the activity of the individual components. Since ribosomal dimerization throttles the translational capacity of the cell by decreasing the concentration of active ribosomes, we reasoned that genetic ablation of the system via disruption of the genes involved in ribosomal dimerization could increase the activity of lysates made from genetically engineered strains. To probe this hypothesis, I chose to work with two experimental lysate systems. One bacterial, made from *B. subtilis* lacking Hpf factor essential for the 100S formation, and one yeast, made from *Saccharomyces cerevisiae* lacking Stm1 protein that plays a similar role to *B. subtilis* Hpf (Balagopal V., 2011; Ben-Shem A., 2011). The efficiency of translation in lysates was by using a model mRNA encoding luciferase and measuring the luminescence, reported in relative luminescence units (RLU).

For the first set of experiments, I used wild-type *B. subtilis* 168 as well as an isogenic knockout strain in which *hpf* gene was genetically disrupted. The poly-some profile of the cells shows that in the case of the wild type-strain the 100S peak is clearly visible (**Figure 21A**), in the Δhpf mutant 100S peak is lacking (**Figure 21B**).

To systematically test the effect of HPF loss on the efficiency of transcription-translation system, I performed two titrations of the main constituents of the *in vitro* lysate system. Firstly, I optimized the ratio between the compound mix (contains amino acids, ATP and other small molecules that support the biochemical reactions) and cell-free lysate (**Figure 21D**). The highest activity was observed at the 1:1 ratio of the compound mix to cell-free lysate, and the Δhpf lysate was clearly more active. Next, I needed to detect the optimal concentration of magnesium ions since it is crucial for transcription-translation system (Zaher H. S., 2014). Working at the optimal ratio between the compound mix to cell-free lysate, I titrated the final concentration of Mg^{2+} from 7 to 22 mM (**Figure 21E**). The *hpf* knockout lysate was more active than WT lysate, and the optimal activity was observed at 12 mM Mg^{2+} .




Figure 21. Elimination of HPF improves the efficiency of *B. subtilis* coupled transcription-translation system. Polysome profile analysis of translational lysates prepared from wild type (A) and Δhpf (B) lysates demonstrates strictly HPF-dependent 100S ribosomes formation. (D) A cell-free translation system was assembled by combining the compound mix with the cell-free extract. The efficiency of translation was quantified by the activity of the firefly luciferase using the Steady-Glo Luciferase Assay (Promega). Titrations of the compound mix to cell-free extract ratio and magnesium ion concentration (E) in the cell-free translation system. Luminescence readings were taken after incubation for 1 hour at 37 °C. Error bars indicate the standard error of the geometric mean of biological replicates, i.e. independently prepared cell-free extracts ($n \geq 3$). Adapted from (Brodiazhenko T., 2018).

Finally, I performed a similar set of experiments with *S. cerevisiae* cell extracts prepared from wild type and *stm1* Δ *S. cerevisiae*. Again, I first optimised the ratio between the compound mix and lysate and then optimised the concentration of Mg^{2+} ions. In the case of *S. cerevisiae* extracts the activity increased with increased compound mixture concentration, and at 2-fold excess of the compound mixture over the lysate the activity of the *stm1* Δ system was higher than the of the wild type one (Figure 22A). Keeping the 2-fold excess of the compound mixture over the lysate, I have titrated the Mg^{2+} . The maximum activity was observed at 4.5 mM Mg^{2+} , with the *stm1* Δ *S. cerevisiae* lysate robustly outperforming the wild-type lysate throughout the whole Mg^{2+} titration range (Figure 22B).




Figure 22. Elimination of *Stm1* improves the efficiency of *S. cerevisiae* translation system. A cell-free translation system was assembled by combining the compound mix with the cell-free extract. The efficiency of translation was quantified by the activity of firefly luciferase using the Steady-Glo Luciferase Assay (Promega). Titrations of the compound mix to cell-free extract ratio (**B**) and magnesium ion concentration (**C**) in the cell-free translation system. Luminescence readings were taken after incubation for 1 hour at 25 °C. Error bars indicate the standard error of the geometric mean of biological replicates, i.e., independently prepared cell-free extracts ($n \geq 3$). Adapted from (Brodiazhenko T., 2018).

Our study serves as a first step towards developing even more active lysates. The strains with ablated ribosome dimerization can be further engineered by, for instance, expression of rare tRNAs, deleting components of protein degradation machinery.

CONCLUSIONS

The main conclusions of the work presented in this thesis are:

- i) Enzymatic activities of RSH enzymes are not limited to production and degradation of (p)ppGpp. Members of toxSAS RSH PhRel2, FaRel2, PhRel and CapRel subfamilies catalyse pyrophosphorylation of tRNA 3'CCA end, and members of FaRel family catalyse synthesis of (pp)pApp. Members of SAH subfamily MESH1 and ATfaRel catalyse removal of the pyrophosphate from PP-tRNA and degradation of (pp)pApp.
- ii) Antitoxins containing common Panacea (PanA) domain neutralize diverse toxin families (PanT). PanA-mediated PanT neutralisation is highly specific for cognate toxin-antitoxin pair.
- iii) Genetic elimination of ribosome dimerization factors in Firmicute bacterium *B. subtilis* (*hfp*) and yeast *S. cerevisiae* (*stm1*) strains is a promising strategy for producing more active *in vitro* translation lysates. Loss of *hfp* and *stm1* fully eliminates the formation of translationally inactive ribosomal dimers in bacteria and yeast, respectively. Mg^{2+} concentration and the ratio between the lysate and the compound mix was identified as the key parameters that should be optimised for achieving the maximal activity of the lysate.

REFERENCES

- Aakre, C.D., Herrou, J., Phung, T.N., Perchuk, B.S., Crosson, S., and Laub, M.T. (2015). Evolving new protein-protein interaction specificity through promiscuous intermediates. *Cell* *163*, 594–606.
- Aakre, C.D., Phung, T.N., Huang, D., and Laub, M.T. (2013). A bacterial toxin inhibits DNA replication elongation through a direct interaction with the beta sliding clamp. *Mol Cell* *52*, 617–628.
- Aberg A., F.-V.J., Cabrer-Panes J. D., Sánchez A., and Balsalobre C. (2009). Similar and divergent effects of ppGpp and DksA deficiencies on transcription in *Escherichia coli*. *J Bacteriol* *191*, 3226–3236.
- Aberg A., S.V., and Balsalobre C. (2008). Regulation of the *fimB* promoter: a case of differential regulation by ppGpp and DksA in vivo. *Mol Microbiol* *67*, 1223–1241.
- Abranches, J., Martinez, A.R., Kajfasz, J.K., Chavez, V., Garsin, D.A., and Lemos, J.A. (2009). The molecular alarmone (p)ppGpp mediates stress responses, vancomycin tolerance, and virulence in *Enterococcus faecalis*. *J Bacteriol* *191*, 2248–2256.
- Ahmad, S., Wang, B., Walker, M.D., Tran, H.R., Stogios, P.J., Savchenko, A., Grant, R.A., McArthur, A.G., Laub, M.T., and Whitney, J.C. (2019). An interbacterial toxin inhibits target cell growth by synthesizing (p)ppApp. *Nature* *575*, 674–678.
- Aiso, T., Yoshida, H., Wada, A., Ohki, R. (2005). Modulation of mRNA stability participates in stationary-phase-specific expression of ribosome modulation factor. *J Bacteriol* *187*, 1951–1958.
- al., R.f.M.e. (2018). Bacterial persistence by RNA endonucleases. *Proc Natl Acad Sci U S A* *115*, E2901.
- Anderson B. W., L.K., Wolak C., Dubiel K., She F., Satyshur K. A., Keck J. L., Wang J. D. (2019). Evolution of (p)ppGpp-HPRT regulation through diversification of an allosteric oligomeric interaction. *Elife* *8*, 47534.
- Anderson, B.W., Fung, D.K., and Wang, J.D. (2021). Regulatory Themes and Variations by the Stress-Signaling Nucleotide Alarmones (p)ppGpp in Bacteria. *Annu Rev Genet* *55*, 115–133.
- Arenz, S., Abdelshahid, M., Sohmen, D., Payoe, R., Starosta, A.L., Berninghausen, O., Haurlyiuk, V., Beckmann, R., and Wilson, D.N. (2016). The stringent factor RelA adopts an open conformation on the ribosome to stimulate ppGpp synthesis. *Nucleic Acids Res* *44*, 6471–6481.
- Atkinson, G.C., Tenson, T., and Haurlyiuk, V. (2011). The RelA/SpoT homolog (RSH) superfamily: distribution and functional evolution of ppGpp synthetases and hydrolases across the tree of life. *PLoS One* *6*, e23479.
- Avarbock, D., Avarbock, A., and Rubin, H. (2000). Differential regulation of opposing RelMtb activities by the aminoacylation state of a tRNA.ribosome.mRNA.RelMtb complex. *Biochemistry* *39*, 11640–11648.
- Balagopal V., a.P.R. (2011). Stm1 modulates translation after 80S formation in *Saccharomyces cerevisiae*. *RNA* *17*, 835–842.
- Belitsky, B.R., Sonenshein, A. L. (2013). Genome-wide identification of *Bacillus subtilis* CodY-binding sites at single-nucleotide resolution. *Proc Natl Acad Sci U S A* *110*, 7026–7031.
- Beljantseva, J., Kudrin, P., Andresen, L., Shingler, V., Atkinson, G.C., Tenson, T., and Haurlyiuk, V. (2017). Negative allosteric regulation of *Enterococcus faecalis* small alarmone synthetase RelQ by single-stranded RNA. *Proc Natl Acad Sci U S A* *114*, 3726–3731.

- Ben-Shem A., G.D.L.N., Melnikov S., Jenner L., Yusupova G., and Yusupov M. (2011). The structure of the eukaryotic ribosome at 3.0 Å resolution. *Science* 334, 1524–1529.
- Bordes, P., Cirinesi, A. M., Ummels, R., Sala, A., Sakr, S., Bitter, W., Genevoux, P. (2011). SecB-like chaperone controls a toxin-antitoxin stress-responsive system in *Mycobacterium tuberculosis*. *Proc Natl Acad Sci U S A* 108, 8438–8443.
- Brodiazhenko T., J.M.J.O., Takada H., Nissan T., Hauryliuk V., and Murina V. (2018). Elimination of Ribosome Inactivating Factors Improves the Efficiency of *Bacillus subtilis* and *Saccharomyces cerevisiae* Cell-Free Translation Systems. *Front Microbiol* 18, 3041.
- Brown, A., Fernandez, I.S., Gordiyenko, Y., and Ramakrishnan, V. (2016). Ribosome-dependent activation of stringent control. *Nature* 534, 277–280.
- Bruhn-Olszewska, B., Molodtsov, V., Sobala, M., Dylewski, M., Murakami, K.S., Cashel, M., and Potrykus, K. (2018). Structure-function comparisons of (p)ppApp vs (p)ppGpp for *Escherichia coli* RNA polymerase binding sites and for rrnB P1 promoter regulatory responses in vitro. *Biochim Biophys Acta Gene Regul Mech* 1861, 731–742.
- Cabrer-Panes J. D., F.-C.L., Fernández-Vázquez J., Gaviria-Cantín T. C., El Mouali Y., Åberg A., Balsalobre C. (2020). ppGpp mediates the growth phase-dependent regulation of agn43, a phase variable gene, by stimulating its promoter activity. *Environ Microbiol Rep* 12, 444–453.
- Cai, Y., Usher, B., Gutierrez, C., Tolcan, A., Mansour, M., Fineran, P. C., Condon, C., Neyrolles, O., Genevoux, P., Blower, T. R. (2020). A nucleotidyltransferase toxin inhibits growth of *Mycobacterium tuberculosis* through inactivation of tRNA acceptor stems. *Sci Adv* 6, 6651.
- Cashel, M. (1975). Regulation of bacterial ppGpp and pppGpp. *Annual Review of Microbiology Vol. 29*, 301–318.
- Cashel, M., and Gallant, J. (1969). Two Compounds implicated in the Function of the RC Gene of *Escherichia coli*. *Nature* 221, 838–841.
- Cashel, M., Kalbacher, B. (1970). The control of ribonucleic acid synthesis in *Escherichia coli*. V. Characterization of a nucleotide associated with the stringent response. *J Biol Chem* 245, 2309–2318.
- Castro-Roa, D., Garcia-Pino, A., De Gieter, S., van Nuland, N. A. J., Loris, R., Zenkin, N. (2013). The Fic protein Doc uses an inverted substrate to phosphorylate and inactivate EF-Tu. *Nat Chem Biol* 9, 811–817.
- Cheverton A. M., G.B., Przydacz M., Wong C. T., Mylona A., Hare S. A., Helaine S. (2016). A *Salmonella* Toxin Promotes Persister Formation through Acetylation of tRNA. *Mol Cell* 63, 86–96.
- Choi, J.S., Kim, W., Suk, S., Park, H., Bak, G., Yoon, J., Lee, Y. (2018). The small RNA, SdsR, acts as a novel type of toxin in *Escherichia coli*. *RNA Biol* 15, 1319–1335.
- Christensen, S.K., and Gerdes, K. (2003). RelE toxins from bacteria and Archaea cleave mRNAs on translating ribosomes, which are rescued by tmRNA. *Mol Microbiol* 48, 1389–1400.
- Corrigan, R.M., Bellows, L.E., Wood, A., and Grundling, A. (2016). ppGpp negatively impacts ribosome assembly affecting growth and antimicrobial tolerance in Gram-positive bacteria. *Proc Natl Acad Sci U S A* 113, E1710–1719.
- Cruz, J.W., Sharp, J. D., Hoffer, E. D., Maehigashi, T., Vvedenskaya, I. O., Konkimalla, A., Husson, R. N., Nickels, B. E., Dunham, C. M., Woychik, N. A. (2015). Growth-regulating *Mycobacterium tuberculosis* VapC-mt4 toxin is an isoacceptor-specific tRNase. *Nat Commun* 6, 7480.

- Culviner, P.H., Laub, M. T. (2018). Global Analysis of the E. coli Toxin MazF Reveals Widespread Cleavage of mRNA and the Inhibition of rRNA Maturation and Ribosome Biogenesis. *MolCell* 70, 868–880.e810.
- Darfeuille, F., Unoson, C., Vogel, J., Wagner, E. G. (2007). An antisense RNA inhibits translation by competing with standby ribosomes. *Mol Cell* 26.
- Dedrick, R.M., Jacobs-Sera, D., Bustamante, C.A., Garlena, R.A., Mavrich, T.N., Pope, W.H., Reyes, J.C., Russell, D.A., Adair, T., Alvey, R., *et al.* (2017). Prophage-mediated defence against viral attack and viral counter-defence. *Nat Microbiol* 2, 16251.
- Ding, C.C., Rose, J., Sun, T., Wu, J., Chen, P. H., Lin, C. C., Yang, W. H., Chen, K. Y., Lee, H., Xu, E., Tian, S., Akinwuntan, J., Zhao, J., Guan, Z., Zhou, P., Chi, J. T. (2020). MESH1 is a cytosolic NADPH phosphatase that regulates ferroptosis. *Nat Metab* 2, 270–277.
- Durfee, T., Hansen, A. M., Zhi, H., Blattner, F. R., Jin, D. J. (2008). Transcription profiling of the stringent response in Escherichia coli. *J Bacteriol* 190, 1084–1096.
- Edwards, A.N., Patterson-Fortin, L. M., Vakulskas, C. A., Mercante, J. W., Potrykus, K., Vinella, D., Camacho, M. I., Fields, J. A., Thompson, S. A., Georgellis, D., Cashel, M., Babitzke, P., Romeo, T. (2011). Circuitry linking the Csr and stringent response global regulatory systems. *Mol Microbiol* 80, 1561–1580.
- Erllich H., L.T., Gallant J. (1971). ppGpp formation in Escherichia coli treated with rifampicin. *J Biol Chem* 245, 6121–6123.
- Fernández-Coll L., C.M. (2020). Possible Roles for Basal Levels of (p)ppGpp: Growth Efficiency Vs. Surviving Stress. *Front Microbiol* 11, 592718.
- Fineran, P.C., Blower, T. R., Foulds, I. J., Humphreys, D. P., Lilley, K. S., Salmond, G. P. (2009). The phage abortive infection system, ToxIN, functions as a protein-RNA toxin-antitoxin pair. *Proc Natl Acad Sci U S A* 106, 894–899.
- Fozo, E.M., Kawano, M., Fontaine, F., Kaya, Y., Mendieta, K. S., Jones, K. L., Ocampo, A., Rudd, K. E., Storz, G. (2008). Repression of small toxic protein synthesis by the Sib and OhsC small RNAs. *Mol Microbiol* 70, 1305.
- Freire, D.M., Gutierrez, C., Garza-Garcia, A., Grabowska, A. D., Sala, A. J., Ariyachakun, K., Panikova, T., Beckham, K. S. H., Colom, A., Pogenberg, V., Cianci, M., Tuukkanen, A., Boudehen, Y. M., Peixoto, A., Botella, L., Svergun, D. I., Schnappinger, D., Schneider, T. R., Genevaux, P., de Carvalho, L. P. S., Wilmanns, M., Parret, A. H. A., Neyrolles, O. (2019). An NAD⁺ Phosphorylase Toxin Triggers Mycobacterium tuberculosis Cell Death. *MolCell* 73, 1282–1291.
- Gaca, A.O., Colomer-Winter, C., and Lemos, J.A. (2015). Many means to a common end: the intricacies of (p)ppGpp metabolism and its control of bacterial homeostasis. *J Bacteriol* 197, 1146–1156.
- Geiger, T., Kastle, B., Gratani, F.L., Goerke, C., and Wolz, C. (2014). Two small (p)ppGpp synthases in Staphylococcus aureus mediate tolerance against cell envelope stress conditions. *J Bacteriol* 196, 894–902.
- Geiger, T., Wolz, C. I. (2014). Intersection of the stringent response and the CodY regulon in low GC Gram-positive bacteria. *Int J Med Microbiol* 304, 150–155.
- Gentry, D.R., and Cashel, M (1995). Cellular localization of the Escherichia coli SpoT protein. *J Bacteriol* 177, 3890–3893.
- Gerdes, K., Bech, F.W., Jorgensen, S.T., Lobner-Olesen, A., Rasmussen, P.B., Atlung, T., Boe, L., Karlstrom, O., Molin, S., and von Meyenburg, K. (1986). Mechanism of post-segregational killing by the hok gene product of the parB system of plasmid R1 and its homology with the relF gene product of the E. coli relB operon. *Embo j* 5, 2023–2029.

- Gerdes, K., Helin, K., Christensen, O. W., Løbner-Olesen, A. (1988). Translational control and differential RNA decay are key elements regulating postsegregational expression of the killer protein encoded by the parB locus of plasmid R1. *J Mol Biol* 203, 119–129.
- Giramma, C.N., DeFoer, M.B., and Wang, J.D. (2021). The Alarmone (p)ppGpp Regulates Primer Extension by Bacterial Primase. *J Mol Biol* 433, 167189.
- Gobert, A., Bruggeman, M., and Giege, P. (2019). Involvement of PIN-like domain nucleases in tRNA processing and translation regulation. *IUBMB Life* 71, 1117–1125.
- Goormaghtigh, F., Fraikin, N., Putrins, M., Hallaert, T., Haurlyuk, V., Garcia-Pino, A., Sjodin, A., Kasvandik, S., Udekwu, K., Tenson, T., *et al.* (2018). Reassessing the Role of Type II Toxin-Antitoxin Systems in Formation of Escherichia coli Type II Persister Cells. *mBio* 9.
- Goyal, A., Belardinelli, R., Maracci, C., Milón, P., Rodnina, M. V. (2015). Directional transition from initiation to elongation in bacterial translation. *Nucleic Acids Res* 43, 10700–10712.
- Guegler, C.K., and Laub, M.T. (2021). Shutoff of host transcription triggers a toxin-antitoxin system to cleave phage RNA and abort infection. *Mol Cell* 81, 2361–2373 e2369.
- Harms, A., Brodersen, D.E., Mitarai, N., and Gerdes, K. (2018). Toxins, Targets, and Triggers: An Overview of Toxin-Antitoxin Biology. *Mol Cell* 70, 768–784.
- Harms, A., Fino, C., Sorensen, M.A., Semsey, S., and Gerdes, K. (2017). Prophages and Growth Dynamics Confound Experimental Results with Antibiotic-Tolerant Persister Cells. *mBio* 8.
- Haseltine, W.A., and Block, R. (1973). Synthesis of guanosine tetra- and pentaphosphate requires the presence of a codon-specific, uncharged transfer ribonucleic acid in the acceptor site of ribosomes. *Proc Natl Acad Sci U S A* 70, 1564–1568.
- Haugen, S.P., Ross, W., Gourse, R. L. (2008). Advances in bacterial promoter recognition and its control by factors that do not bind DNA. *Nat Rev Microbiol* 6, 507–519.
- Haurlyuk, V., Atkinson, G.C., Murakami, K.S., Tenson, T., and Gerdes, K. (2015). Recent functional insights into the role of (p)ppGpp in bacterial physiology. *Nat Rev Microbiol* 13, 298–309.
- Hernandez, V.J., and Bremer, H. (1991). Escherichia coli ppGpp synthetase II activity requires spoT. *J Biol Chem* 266, 5991–5999.
- Hobbs, J.K., and Boraston, A.B. (2019). (p)ppGpp and the Stringent Response: An Emerging Threat to Antibiotic Therapy. *ACS Infect Dis* 5, 1505–1517.
- Hogg, T., Mechold, U., Malke, H., Cashel, M., and Hilgenfeld, R. (2004). Conformational antagonism between opposing active sites in a bifunctional RelA/SpoT homolog modulates (p)ppGpp metabolism during the stringent response [corrected]. *Cell* 117, 57–68.
- Izutsu, K., Wada, A., Wada, C. (2001). Expression of ribosome modulation factor (RMF) in Escherichia coli requires ppGpp. *Genes Cells* 6, 665–676.
- Jankevicius, G., Ariza, A., Ahel, M., and Ahel, I. (2016). The Toxin-Antitoxin System DarTG Catalyzes Reversible ADP-Ribosylation of DNA. *Mol Cell* 64, 1109–1116.
- Jensen, R.B., and Gerdes, K. (1995). Programmed cell death in bacteria: proteic plasmid stabilization systems. *Mol Microbiol* 17, 205–210.
- Jiang, M., Sullivan, S. M., Wout, P. K., Maddock, J. R. (2007). G-protein control of the ribosome-associated stress response protein SpoT. *Bacteriol* 189, 6140–6147.

- Jimmy, S., Saha, C.K., Kurata, T., Stavropoulos, C., Oliveira, S.R.A., Koh, A., Cepauskas, A., Takada, H., Rejman, D., Tenson, T., *et al.* (2020). A widespread toxin-antitoxin system exploiting growth control via alarmone signaling. *Proc Natl Acad Sci U S A* *117*, 10500–10510.
- Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Zidek, A., Potapenko, A., *et al.* (2021). Highly accurate protein structure prediction with AlphaFold. *Nature* *596*, 583–589.
- Jumper, J., and Hassabis, D. (2022). Protein structure predictions to atomic accuracy with AlphaFold. *Nature Methods* *19*, 11–12.
- Jurenas, D., Chatterjee, S., Konijnenberg, A., Sobott, F., Droogmans, L., Garcia-Pino, A., and Van Melderen, L. (2017). AtaT blocks translation initiation by N-acetylation of the initiator tRNA(fMet). *Nat Chem Biol* *13*, 640–646.
- Jurenas, D., Fraikin, N., Goormaghtigh, F., and Van Melderen, L. (2022). Biology and evolution of bacterial toxin-antitoxin systems. *Nat Rev Microbiol*.
- Jurenas, D., Van Melderen, L., and Garcia-Pino, A. (2019). Mechanism of regulation and neutralization of the AtaR-AtaT toxin-antitoxin system. *Nat Chem Biol* *15*, 285–294.
- Kaczanowska, M., Rydén-Aulin, M. (2007). Ribosome biogenesis and the translation process in *Escherichia coli*. *Microbiol Mol Biol Rev* *71*, 477–494.
- Kaldalu N., H.V., Turnbull K. J., La Mensa A., Putriņš M., Tenson T. (2020). In Vitro Studies of Persister Cells. *Microbiol Mol Biol Rev* *84*, 00070–00020.
- Kaspy, I., Rotem, E., Weiss, N., Ronin, I., Balaban, N.Q., and Glaser, G. (2013). HipA-mediated antibiotic persistence via phosphorylation of the glutamyl-tRNA-synthetase. *Nat Commun* *4*, 3001.
- Korch, S.B., Henderson, T.A., and Hill, T.M. (2003). Characterization of the hipA7 allele of *Escherichia coli* and evidence that high persistence is governed by (p)ppGpp synthesis. *Mol Microbiol* *50*, 1199–1213.
- Krasny, L., and Gourse, R.L. (2004). An alternative strategy for bacterial ribosome synthesis: *Bacillus subtilis* rRNA transcription regulation. *Embo j* *23*, 4473–4483.
- Kriel, A., Bittner, A.N., Kim, S.H., Liu, K., Tehranchi, A.K., Zou, W.Y., Rendon, S., Chen, R., Tu, B.P., and Wang, J.D. (2012). Direct regulation of GTP homeostasis by (p)ppGpp: a critical component of viability and stress resistance. *Mol Cell* *48*, 231–241.
- Kriel, A., Brinsmade, S.R., Tse, J.L., Tehranchi, A.K., Bittner, A.N., Sonenshein, A.L., and Wang, J.D. (2014). GTP dysregulation in *Bacillus subtilis* cells lacking (p)ppGpp results in phenotypic amino acid auxotrophy and failure to adapt to nutrient downshift and regulate biosynthesis genes. *J Bacteriol* *196*, 189–201.
- Kurata, T., Brodiazhenko, T., Alves Oliveira, S.R., Roghianian, M., Sakaguchi, Y., Turnbull, K.J., Bulvas, O., Takada, H., Tamman, H., Ainelo, A., *et al.* (2021). RelA-SpoT Homolog toxins pyrophosphorylate the CCA end of tRNA to inhibit protein synthesis. *Mol Cell* *81*, 3160–3170 e3169.
- Kurata, T., Saha, C.K., Buttress, J.A., Mets, T., Brodiazhenko, T., Turnbull, K.J., Awoyomi, O.F., Oliveira, S.R.A., Jimmy, S., Ernits, K., *et al.* (2022). A hyper-promiscuous antitoxin protein domain for the neutralization of diverse toxin domains. *Proc Natl Acad Sci U S A* *119*.
- Lazzarini, R.A., Dahlberg, A. E. (1971). The control of ribonucleic acid synthesis during amino acid deprivation in *Escherichia coli*. *J Biol Chem* *246*, 420–429.
- Leplae, R., Geraerts, D., Hallez, R., Guglielmini, J., Dreze, P., and Van Melderen, L. (2011). Diversity of bacterial type II toxin-antitoxin systems: a comprehensive search and functional analysis of novel families. *Nucleic Acids Res* *39*, 5513–5525.

- LeRoux, M., Culviner, P. H., Liu, Y. J., Littlehale, M. L., Laub, M. T. (2020). Stress Can Induce Transcription of Toxin-Antitoxin Systems without Activating Toxin. *J MolCell* 79, 280–292.
- LeRoux, M., Laub, M. T. (2022). Toxin-Antitoxin Systems as Phage Defense Elements. *Annu Rev Microbiol*.
- Li, G.Y., Zhang, Y., Inouye, M., Ikura, M. (2009). Inhibitory mechanism of *Escherichia coli* RelE-RelB toxin-antitoxin module involves a helix displacement near an mRNA interferase active site. *J Biol Chem* 284, 14628–14636.
- Li, M., Gong, L., Cheng, F., Yu, H., Zhao, D., Wang, R., Wang, T., Zhang, S., Zhou, J., Shmakov, S. A., Koonin, E. V., Xiang, H. (2021). Toxin-antitoxin RNA pairs safeguard CRISPR-Cas systems. *Science* 372, eabe5601.
- Liu, K., Bittner, A.N., and Wang, J.D. (2015). Diversity in (p)ppGpp metabolism and effectors. *Curr Opin Microbiol* 24, 72–79.
- Lopatina, A., Tal, N., Sorek, R. (2020). Abortive Infection: Bacterial Suicide as an Antiviral Immune Strategy. *Annu Rev Virol* 7, 371–384.
- Lopez, J.M., Dromerick, A., Freese, E. (1981). Response of guanosine 5'-triphosphate concentration to nutritional changes and its significance for *Bacillus subtilis* sporulation. *JBacteriol* 146, 605–613.
- Loveland, A.B., Bah, E., Madireddy, R., Zhang, Y., Brilot, A.F., Grigorieff, N., and Korostelev, A.A. (2016). Ribosome*RelA structures reveal the mechanism of stringent response activation. *Elife* 5.
- Maciag, M., Kochanowska, M., Lyzen, R., Wegrzyn, G., and Szalewska-Palasz, A. (2010). ppGpp inhibits the activity of *Escherichia coli* DnaG primase. *Plasmid* 63, 61–67.
- Maikova, A., Peltier, J., Boudry, P., Hajnsdorf, E., Kint, N., Monot, M., Poquet, I., Martin-Verstraete, I., Dupuy, B., Soutourina, O. (2018). Discovery of new type I toxin-antitoxin systems adjacent to CRISPR arrays in *Clostridium difficile*. *NucleicAcidsRes* 46, 4733–4751.
- Maisonneuve, E., and Gerdes, K. (2014). Molecular mechanisms underlying bacterial persisters. *Cell* 157, 539–548.
- Manav, M.C., Beljantseva, J., Bojer, M.S., Tenson, T., Ingmer, H., Haurlyuk, V., and Brodersen, D.E. (2018). Structural basis for (p)ppGpp synthesis by the *Staphylococcus aureus* small alarmone synthetase RelP. *J Biol Chem* 293, 3254–3264.
- Masuda, H., Tan, Q., Awano, N., Wu, K.P., and Inouye, M. (2012). YeeU enhances the bundling of cytoskeletal polymers of MreB and FtsZ, antagonizing the CbtA (YeeV) toxicity in *Escherichia coli*. *Mol Microbiol* 84, 979–989.
- Mechold, U., Potrykus, K., Murphy, H., Murakami, K.S., and Cashel, M. (2013). Differential regulation by ppGpp versus pppGpp in *Escherichia coli*. *Nucleic Acids Res* 41, 6175–6189.
- Mets, T., Lippus, M., Schryer, D., Liiv, A., Kasari, V., Paier, A., Maiväli, Ü., Remme, J., Tenson, T., Kaldalu, N. (2017). Toxins MazF and MqsR cleave *Escherichia coli* rRNA precursors at multiple sites. *J RNA Biol* 14, 124–135.
- Milon, P., Carotti, M., Konevega, A. L., Wintermeyer, W., Rodnina, M. V., Gualerzi, C. O. (2010). The ribosome-bound initiation factor 2 recruits initiator tRNA to the 30S initiation complex. *EMBO Rep* 11, 312–316.
- Milon, P., Tischenko, E., Tomsic, J., Caserta, E., Folkers, G., La Teana, A., Rodnina, M. V., Pon, C. L., Boelens, R., Gualerzi, C. O. (2006). The nucleotide-binding site of bacterial translation initiation factor 2 (IF2) as a metabolic sensor. *Proc Natl Acad Sci U S A* 103, 13962–13967.

- Mitkevich, V.A., Ermakov, A., Kulikova, A. A., Tankov, S., Shyp, V., Soosaar, A., Tenson, T., Makarov, A. A., Ehrenberg, M., Hauryliuk, V. (2010). Thermodynamic characterization of ppGpp binding to EF-G or IF2 and of initiator tRNA binding to free IF2 in the presence of GDP, GTP, or ppGpp. *J Mol Biol* 402, 838–846.
- Mittenhuber, G. (2001). Comparative genomics and evolution of genes encoding bacterial (p)ppGpp synthetases/hydrolases (the Rel, RelA and SpoT proteins). *J Mol Microbiol Biotechnol* 3, 585–600.
- Molle, V., Nakaura, Y., Shivers, R. P., Yamaguchi, H., Losick, R., Fujita, Y., Sonenshein, A. L. (2003). Additional targets of the *Bacillus subtilis* global regulator CodY identified by chromatin immunoprecipitation and genome-wide transcript analysis. *J Bacteriol* 185, 1911–1922.
- Murray, K.D., and Bremer, H. (1996). Control of spoT-dependent ppGpp synthesis and degradation in *Escherichia coli*. *J Mol Biol* 259, 41–57.
- Nanamiya, H., Kasai, K., Nozawa, A., Yun, C.S., Narisawa, T., Murakami, K., Natori, Y., Kawamura, F., and Tozawa, Y. (2008). Identification and functional analysis of novel (p)ppGpp synthetase genes in *Bacillus subtilis*. *Mol Microbiol* 67, 291–304.
- Ogura, T., and Hiraga, S. (1983). Mini-F plasmid genes that couple host cell division to plasmid proliferation. *Proc Natl Acad Sci U S A* 80, 4784–4788.
- Oren, A., Garrity, G. M. (2021). Valid publication of the names of forty-two phyla of prokaryotes. *Int J Syst Evol Microbiol* 71.
- Otsuka, Y., Yonesaki, T. (2005). A novel endoribonuclease, RNase LS, in *Escherichia coli*. *Genetics* 169, 13–20.
- Paul, B.J., Barker, M.M., Ross, W., Schneider, D.A., Webb, C., Foster, J.W., and Gourse, R.L. (2004). DksA: a critical component of the transcription initiation machinery that potentiates the regulation of rRNA promoters by ppGpp and the initiating NTP. *Cell* 118, 311–322.
- Paul, B.J., Berkmen, M.B., and Gourse, R.L. (2005). DksA potentiates direct activation of amino acid promoters by ppGpp. *Proc Natl Acad Sci U S A* 102, 7823–7828.
- Pedersen K., Z.A.V., Pavlov M. Y., Elf J., Gerdes K., Ehrenberg M. (2003). The bacterial toxin RelE displays codon-specific cleavage of mRNAs in the ribosomal A site. *Cell* 112, 131–140.
- Pizarro-Cerdá J., a.T.K. (2004). The bacterial signal molecule, ppGpp, regulates *Salmonella* virulence gene expression. *Mol Microbiol* 52, 1827–1844.
- Potrykus, K., and Cashel, M. (2008). (p)ppGpp: still magical? *Annu Rev Microbiol* 62, 35–51.
- Potrykus, K., Thomas, N.E., Bruhn-Olszewska, B., Sobala, M., Dylewski, M., James, T., and Cashel, M. (2020). Estimates of RelSeq, Mesh1, and SAHMex Hydrolysis of (p)ppGpp and (p)ppApp by Thin Layer Chromatography and NADP/NADH Coupled Assays. *Front Microbiol* 11, 581271.
- Roberts, R.C., Ström, A. R., Helinski, D. R. (1994). The parDE operon of the broad-host-range plasmid RK2 specifies growth inhibition associated with plasmid loss. *J Mol Biol* 237, 35–51.
- Rodnina, M.V. (2018). Translation in Prokaryotes. *Cold Spring Harb Perspect Biol* 10, a032664.
- Roghianian, M., Van Nerom, K., Takada, H., Caballero-Montes, J., Tamman, H., Kudrin, P., Talavera, A., Dzhygyr, I., Ekstrom, S., Atkinson, G.C., *et al.* (2021). (p)ppGpp controls stringent factors by exploiting antagonistic allosteric coupling between catalytic domains. *Mol Cell* 81, 3310–3322 e3316.

- Ronneau, S., Helaine, S. (2019). Clarifying the Link between Toxin-Antitoxin Modules and Bacterial Persistence. *JMolBiol* 413, 3462–3471.
- Ross, W., Sanchez-Vazquez, P., Chen, A.Y., Lee, J.H., Burgos, H.L., and Gourse, R.L. (2016). ppGpp Binding to a Site at the RNAP-DksA Interface Accounts for Its Dramatic Effects on Transcription Initiation during the Stringent Response. *Mol Cell* 62, 811–823.
- Ross, W., Vrentas, C.E., Sanchez-Vazquez, P., Gaal, T., and Gourse, R.L. (2013). The magic spot: a ppGpp binding site on E. coli RNA polymerase responsible for regulation of transcription initiation. *Mol Cell* 50, 420–429.
- Ruwe, M., Kalinowski, J., and Persicke, M. (2017). Identification and Functional Characterization of Small Alarmone Synthetases in *Corynebacterium glutamicum*. *Front Microbiol* 8, 1601.
- Ruwe, M., Ruckert, C., Kalinowski, J., and Persicke, M. (2018). Functional Characterization of a Small Alarmone Hydrolase in *Corynebacterium glutamicum*. *Front Microbiol* 9, 916.
- Saha, C.K., Sanches Pires, R., Brolin, H., Delannoy, M., and Atkinson, G.C. (2021). FlaGs and webFlaGs: discovering novel biology through the analysis of gene neighbourhood conservation. *Bioinformatics* 37, 1312–1314.
- Samson, J.E., Spinelli, S., Cambillau, C., Moineau, S. (2013). Structure and activity of AbiQ, a lactococcal endoribonuclease belonging to the type III toxin-antitoxin system. *Mol Microbiol* 87, 756–768.
- Schäfer H., B.B., Frese C. K., Steinchen W., Nuss A. M., Beckstette M., Hantke I., Driller K., Sudzinová P., Krásný L., Kaefer V., Dersch P., Bange G., Wilson D. N., Turgay K.. (2020). The alarmones (p)ppGpp are part of the heat shock response of *Bacillus subtilis*. *PLoS Genet* 16, 1008275.
- Seyfzadeh, M., Keener, J., and Nomura, M. (1993). spoT-dependent accumulation of guanosine tetraphosphate in response to fatty acid starvation in *Escherichia coli*. *Proc Natl Acad Sci U S A* 90, 11004–11008.
- Shyp, V., Tankov, S., Ermakov, A., Kudrin, P., English, B.P., Ehrenberg, M., Tenson, T., Elf, J., and Haurlyuk, V. (2012). Positive allosteric feedback regulation of the stringent response enzyme RelA by its product. *EMBO Rep* 13, 835–839.
- Sinha, A.K., Winther, K. S., Roghanian, M., Gerdes, K. (2019). Fatty acid starvation activates RelA by depleting lysine precursor pyruvate. *Mol Microbiol* 112, 1339–1349.
- Slack, F.J., Serron, P., Joyce, E., Sonenshein, A. L. (1995). A gene required for nutritional repression of the *Bacillus subtilis* dipeptide permease operon. *Mol Microbiol* 15, 689–702.
- Sonenshein, A.L. (2007). Control of key metabolic intersections in *Bacillus subtilis*. *Nat Rev Microbiol* 5, 917–927.
- Songailiene, I., Juozapaitis, J., Tamulaitiene, G., Ruksenaite, A., Šulčius, S., Sasnauskas, G., Venclovas, Č., Siksnyš, V. (2020). HEPN-MNT Toxin-Antitoxin System: The HEPN Ribonuclease Is Neutralized by OligoAMPylation. *Mol Cell* 80, 955–970.
- Steinchen, W., Ahmad, S., Valentini, M., Eilers, K., Majkini, M., Altegoer, F., Lechner, M., Filloux, A., Whitney, J.C., and Bange, G. (2021). Dual role of a (p)ppGpp- and (p)ppApp-degrading enzyme in biofilm formation and interbacterial antagonism. *Mol Microbiol* 115, 1339–1356.
- Steinchen, W., Schuhmacher, J.S., Altegoer, F., Fage, C.D., Srinivasan, V., Linne, U., Marahiel, M.A., and Bange, G. (2015). Catalytic mechanism and allosteric regulation

- of an oligomeric (p)ppGpp synthetase by an alarmone. *Proc Natl Acad Sci U S A* *112*, 13348–13353.
- Steinchen, W., Vogt, M.S., Altegoer, F., Giammarinaro, P.I., Horvatek, P., Wolz, C., and Bange, G. (2018). Structural and mechanistic divergence of the small (p)ppGpp synthetases RelP and RelQ. *Sci Rep* *8*, 2195.
- Stent, G.S., and Brenner, S. (1961). A genetic locus for the regulation of ribonucleic acid synthesis. *Proc Natl Acad Sci U S A* *47*, 2005–2014.
- Sun, D., Lee, G., Lee, J.H., Kim, H.Y., Rhee, H.W., Park, S.Y., Kim, K.J., Kim, Y., Kim, B.Y., Hong, J.I., *et al.* (2010). A metazoan ortholog of SpoT hydrolyzes ppGpp and functions in starvation responses. *Nat Struct Mol Biol* *17*, 1188–1194.
- Svenningsen M. S., V.A., Harms A., Mitarai N., and Semsey S. (2019). Birth and resuscitation of (p)ppGpp induced antibiotic tolerant persister cells. *Sci Rep* *9*, 6056.
- Svitil A. L., C.M., Zyskind J. W. (1993). Guanosine tetraphosphate inhibits protein synthesis in vivo. A possible protective mechanism for starvation stress in *Escherichia coli*. *J Biol Chem* *268*, 2307–2311.
- Sy, J. (1977). In vitro degradation of guanosine 5'-diphosphate, 3'-diphosphate. *Proc Natl Acad Sci U S A* *74*, 5529–5533.
- Tagami, K., Nanamiya, H., Kazo, Y., Maehashi, M., Suzuki, S., Namba, E., Hoshiya, M., Hanai, R., Tozawa, Y., Morimoto, T., Ogasawara, N., Kageyama, Y., Ara, K., Ozaki, K., Yoshida, M., Kuroiwa, H., Kuroiwa, T., Ohashi, Y., & Kawamura, F. (2012). Expression of a small (p)ppGpp synthetase, YwaC, in the (p)ppGpp(0) mutant of *Bacillus subtilis* triggers YvyD-dependent dimerization of ribosome. *MicrobiologyOpen* *1*, 115–134.
- Takada, H., Roghanian, M., Caballero-Montes, J., Van Nerom, K., Jimmy, S., Kudrin, P., Trebini, F., Murayama, R., Akanuma, G., Garcia-Pino, A., *et al.* (2021). Ribosome association primes the stringent factor Rel for tRNA-dependent locking in the A-site and activation of (p)ppGpp synthesis. *Nucleic Acids Res* *49*, 444–457.
- Tam, J.E., Kline, B. C. (1989). The F plasmid *ccd* autorepressor is a complex of CcdA and CcdB proteins. *Mol Gen Genet* *219*, 26–32.
- Texier, P., Bordes, P., Nagpal, J., Sala, A. J., Mansour, M., Cirinesi, A. M., Xu, X., Dougan, D. A., Genevaux, P. (2021). ClpXP-mediated Degradation of the TAC Antitoxin is Neutralized by the SecB-like Chaperone in *Mycobacterium tuberculosis*. *J Mol Biol* *433*, 166815.
- Travis, B.A., and Schumacher, M.A. (2021). Diverse molecular mechanisms of transcription regulation by the bacterial alarmone ppGpp. *Mol Microbiol*.
- Traxler, M.F., Summers, S. M., Nguyen, H. T., Zacharia, V. M., Hightower, G. A., Smith, J. T., Conway, T. (2008). The global, ppGpp-mediated stringent response to amino acid starvation in *Escherichia coli*. *Mol Microbiol* *68*, 1128–1148.
- Traxler, M.F., Zacharia, V. M., Marquardt, S., Summers, S. M., Nguyen, H. T., Stark, S. E., Conway, T. (2011). Discretely calibrated regulatory loops controlled by ppGpp partition gene induction across the 'feast to famine' gradient in *Escherichia coli*. *Mol Microbiol* *79*, 830–845.
- Tsuchimoto, S., Ohtsubo, H., Ohtsubo, E. (1988). Two genes, *pemK* and *pemI*, responsible for stable maintenance of resistance plasmid R100. *JBacteriol* *170*, 1461–1466.
- Van Melderen, L., Bernard, P., and Couturier, M. (1994). Lon-dependent proteolysis of CcdA is the key control for activation of CcdB in plasmid-free segregant bacteria. *Mol Microbiol* *11*, 1151–1157.

- Van Nerom, K., Tamman, H., Takada, H., Hauryliuk, V., and Garcia-Pino, A. (2019). The Rel stringent factor from *Thermus thermophilus*: crystallization and X-ray analysis. *Acta Crystallogr F Struct Biol Commun* 75, 561–569.
- Varik, V., Oliveira, S.R.A., Hauryliuk, V., and Tenson, T. (2017). HPLC-based quantification of bacterial housekeeping nucleotides and alarmone messengers ppGpp and pppGpp. *Sci Rep* 7, 11022.
- Verstraeten, N., Knapen, W.J., Fauvart, M., and Michiels, J. (2015). Membrane depolarization-triggered responsive diversification leads to antibiotic tolerance. *Microb Cell* 2, 299–301.
- Vinella, D., Albrecht, C., Cashel, M., D'Ari, R. (2005). Iron limitation induces SpoT-dependent accumulation of ppGpp in *Escherichia coli*. *Mol Microbiol* 56, 958–970.
- Vinogradova, D.S., Zegarra, V., Maksimova, E., Nakamoto, J.A., Kasatsky, P., Paleskava, A., Konevega, A.L., and Milon, P. (2020). How the initiating ribosome copes with ppGpp to translate mRNAs. *PLoS Biol* 18, e3000593.
- Wada A., Y. Y., Fujita N., and Ishihama A. (1990). Structure and probable genetic location of a “ribosome modulation factor” associated with 100S ribosomes in stationary-phase *Escherichia coli* cells. *Proc Natl Acad Sci USA* 87, 2657–2661.
- Wagner, R. (2002). Regulation of ribosomal RNA synthesis in *E. coli*: effects of the global regulator guanosine tetraphosphate (ppGpp). *Mol Microbiol Biotechnol* 4, 331–340.
- Wang, X., Lord, D.M., Cheng, H.Y., Osbourne, D.O., Hong, S.H., Sanchez-Torres, V., Quiroga, C., Zheng, K., Herrmann, T., Peti, W., *et al.* (2012). A new type V toxin-antitoxin system where mRNA for toxin GhoT is cleaved by antitoxin GhoS. *Nat Chem Biol* 8, 855–861.
- Wein, T., Sorek, R. (2022). Bacterial origins of human cell-autonomous innate immune mechanisms. *Nat Rev Immunol*.
- Williams, K.P., Gillespie, J. J., Sobral, B. W., Nordberg, E.K., Snyder, E. E., *et al.* (2010). Phylogeny of gammaproteobacteria. *J Bacteriol* 192, 2305–2314.
- Winther, K.S., and Gerdes, K. (2011). Enteric virulence associated protein VapC inhibits translation by cleavage of initiator tRNA. *Proc Natl Acad Sci U S A* 108, 7403–7407.
- Xiao, H., Kalman, M., Ikehara, K., Zemel, S., Glaser, G., and Cashel, M. (1991). Residual guanosine 3',5'-bispyrophosphate synthetic activity of relA null mutants can be eliminated by spoT null mutations. *J Biol Chem* 266, 5980–5990.
- Yamagishi, M., Matsushima, H., Wada, A., Sakagami, M., Fujita, N., Ishihama, A. (1993). Regulation of the *Escherichia coli* *rmf* gene encoding the ribosome modulation factor: growth phase- and growth rate-dependent control. *EMBO J* 12, 625–630.
- Yamaguchi, Y., Park, J.H., and Inouye, M. (2009). MqsR, a crucial regulator for quorum sensing and biofilm formation, is a GCU-specific mRNA interferase in *Escherichia coli*. *J Biol Chem* 284, 28746–28753.
- Yoshida, H., and Wada, A. (2014). The 100S ribosome: ribosomal hibernation induced by stress. *Wiley Interdiscip Rev RNA* 5, 723–732.
- Yu, X., Gao, X., Zhu, K., Yin, H., Mao, X., Wojdyla, J. A., Qin, B., Huang, H., Wang, M., Sun, Y. C., Cui, S. (2020). Characterization of a toxin-antitoxin system in *Mycobacterium tuberculosis* suggests neutralization by phosphorylation as the antitoxicity mechanism. *Commun Biol* 3, 216.
- Yuan J., S.Y., Mitchenall L. A., Maxwell A., Loris R., Waldor M. K. (2010). *Vibrio cholerae* ParE2 poisons DNA gyrase via a mechanism distinct from other gyrase inhibitors. *J Biol Chem* 285, 40397–40408.

- Zaher H. S., a.G.R. (2014). In vitro synthesis of proteins in bacterial extracts. *Methods Enzymol* 539, 3–15.
- Zhang, T., Tamman, H., Coppieters't Wallant, K., Kurata, T., LeRoux, M., Srikant, S., Brodiazhenko, T., Cepauskas, A., Talavera, A., Martens, C., *et al.* (2022). Direct activation of an innate immune system in bacteria by a viral capsid protein. *bioRxiv*, 2022.2005.2030.493996.

SUMMARY IN ESTONIAN

RelA-SpoT valguperekonna ensüümid kui Toksiin-Antitoksiin süsteemide osalised

Nagu kõik elusorganismid, tunnetavad bakterid keskkonda ja reageerivad suurele hulgale erinevatele stressidele, kohandades vastavalt oma füsioloogiat.

Üks peamisi stressivastuseid on poomisvastus. Poomisvastus vahendab bakterite kohanemist toitainete vähesusega, samuti vastust abiootilisele keskkonnastressidele nagu näiteks kuumašokk. Rohkem kui kuus aastakümnet tagasi avastati, et häirenukleotiidid ppGpp ja pppGpp – ühiselt viidatud kui (p)ppGpp – ehk maagilised laigud tekivad *Escherichia coli* rakkudes vastusena aminohapete vähesusele. Poomisvastuse esimene füsioloogiline roll, mis tuvastati, oli stabiilse RNA (rRNA ja tRNA) sünteesi pärssimine, mis on kooskõlastatud aminohapete biosünteesi ja stressitaluvusega seotud geenide ekspressiooni indutseerimisega. Aastakümneid kestnud uuringud on aga näidanud, et lisaks transkriptsioonile on (p)ppGpp sihtmärkideks ka mitmed muud rakus toimuvad protsessid, nagu translatsioon, ribosoomide kokkupanek, antibiootikumiresistentsus ja virulentsus.

Veel üks oluline bakterite regulatsioonisüsteem põhineb toksiini – antitoksiini (TA) süsteemidel. Esimesed toksiini-antitoksiin (TA) süsteemide esindajad avastati 80ndate alguses. Klassikalised TA süsteemid on bitsistronilised – st koosnevad kahest geenist – operonist, milles üks geen kodeerib valgulist toksiini ja teine antitoksiini, valku või RNAd, mis toksiini kas otseselt või kaudselt neutraliseerib. TA-süsteemide uuringud on viimastel aastatel plahvatuslikult kasvanud, avastatud on arvukalt uusi TA perekondi, iseloomustatud nende toimemehhanisme, iseloomustatud bioloogilisi funktsioone ja pakutud välja võimalikke rakendusi biotehnoloogias. Enim iseloomustatud funktsioonid hõlmavad plasmidi säilitamist, kaitset bakteriofaagide vastu ja rakufüsioloogia reguleerimist.

Käesolevas uuringus kirjeldati RSH perekonna ensüümide uusi aktiivsusi ja toksiinide neutraliseerimise spetsiifilisust PanA antitoksiini perekonna liikmete poolt.

Lisaks eelpool kirjeldatud protsessidele toimub stressi ajal ribosoomide dimerisatsioon. See stressivastus on kasulik rakkudele ellujäämiseks, kuid võib lüsaatide kasutamise korral biotehnoloogias olla probleemiks kuna vähendab rakuvabade translatsioonisüsteemide aktiivsust. Seetõttu uuriti ribosoomi dimeriseerumise eest vastutavate valkude eemaldamise mõju rakulüsaatide aktiivsusele.

Leiti, et RSH ensüümide ensümaatiline aktiivsus ei piirdu (p)ppGpp tootmise ja lagunemisega. ToxSAS RSH PhRel2, FaRel2, PhRel ja CapRel alamperekondade liikmed katalüüsivad tRNA 3'CCA otsa pürofosforüülimist ja FaRel perekonna liikmed katalüüsivad (pp)pApp sünteesi. SAH alamperekonna liikmed MESH1 ja ATfaRel katalüüsivad pürofosfaadi eemaldamist PP-tRNA-st ja (pp)pApp lagunemist.

Ühist PanA domeeni sisaldavad antitoksiinid neutraliseerivad erinevaid toksiiine. PanA-vahendatud toksiiinide neutraliseerimine on toksiiini osas siiski spetsiifiline.

Ribosoomi dimerisatsioonifaktorite geneetiline elimineerimine bakteri *B. subtilis* (hfp) ja pärmis *S. cerevisiae* (stm1) tüvedes on paljulubav strateegia aktiivsemate rakuvabade translatsioonilüsaatide tootmiseks. Reaktsiooni optimeerimisel on oluline panna tähele Mg^{2+} ja muude komponentide kontsentratsioone ja omavahelisi suhteid.

ACKNOWLEDGMENTS

My sincere gratitude goes to my supervisors **Dr. Vasili Hauryluik** and **Professor Tanel Tenson** for giving me the opportunity to be part of the lab to do the PhD. I would like to thank them for all the patience and opportunities that they gave to me during my studies at the University of Tartu and University of Umeå.

Next, I would like to express my acknowledgments to my colleagues from Tartu and Umeå/Lund lab in chronological order. Special thanks to **Victoriia Murina** from Umeå lab who was my first teacher and helped me to start my journey in science. **Sofia R. A. Oliveira** my personal thanks for your huge help during my first year and following years and for teaching me how to operate HPLC. **Tatsuaki Kurata** for teaching me metabolic labelling assay. Also, I would like to thank **Mohammad (Mo) Roghanian** and **Kathryn J. Turnbull** for the general and scientific support during my PhD life and just for being awesome scientist and people! From now, I am considering changing my name from Tanya to Tatyovsky! **Karin Ernits** – you one of the greatest Estonian whom I know, and one of the best people whom I met. Thanks, you and your **Family (Varmo Ernits, Gretaliis, Egert and small Rihard)** for all support! My personal recognition goes to my lab's brother- **Chayan Kumar Saha**! Thanks for all the coffee walks to the hospital and in general for all the huge support from you! Wish you happy marriage!

From Tartu side my special gratitude goes to my awesome Estonian colleague **Toomas Mets**! I will never forget our fun talks in the office and preparation for the phage course! **Krõõt Arbo**- you and your family made me really feel like home and welcome! And you have the best cats in the world!!! Special thanks to **Jelena Beljantseva** who not just colleague but also close friend in Tartu. I will always be very grateful for all what you are done for me!!! Thanks to my new students **Aytan** and **Liza** who helped me to write this thesis by doing all my lab work!

Finally, I would like to say all the thanks to my friends: Odesa's friend **Mykola Shtenikov** for support and smart guidance. **Marina Lozan** for being my sister from our high school time, **Kateryna Moskalenko** and **Anastasiia Lozova** for the general support and being one of my best friends in this life. **Anastasiia Kruchanova** for preparing to be a responsible adult and for smart and wise advice. You and **Martin Kassar** one of the best marriage couples whom I know! **Ana H. D. Oliveira** (not **Sofia** sister as I thought in the beginning). I am very happy that met you and hope that we can be in touch for years. Without you it would be impossible to complete this PhD, thanks for being here for me! Wish you all the best in your post PhD life!! Thanks also to my new Estonian friends: **Risto**, **Hans** and **Elis** who were keeping me company in Säde during my writing.

Last, but not least big thanks to my **Family** especially my **Grandma**. Because of your help I am writing thesis now! Thank you for all your support during hard time. Дякую тобі **Люда** за все що ти для мене зробила та дякую що ти наглядаєш за котами поки мене не має поруч. Сумую дуже сильно за тобою! A big thank you to **all members of Tenson's and Hauryluik's lab** for welcoming me so well in Tartu and Umeå and for everything that I have learned from all of them during my studies!

PUBLICATIONS

CURRICULUM VITAE

Name: Tetiana Brodiazhenko
Date of birth: 17/09/1995
Citizenship: Ukrainian
Email: tetiana.brodiazhenko@ut.ee
Phone: +372 589 33705

RESEARCH INTEREST AND EXPERTISE

My research interests are protein biosynthesis, (p)ppGpp-mediated signalling and toxin-antitoxin systems.

SCIENTIFIC DEGREES

- 2018–2022 Ph.D. student in Biomedical Technology, University of Tartu, Faculty of Science and Technology, Institute of Technology, Tartu, Estonia
Supervisors: Professor Tanel Tenson and Dr. Vasili Hauryliuk
Thesis: Small Alarmone Synthetases as effectors of Toxin-Antitoxin systems
- 2016–2018 M.Sc. (Honours) in Microbiology, Faculty of Biology, Odesa I.I. Mechnikov National University, Odesa, Ukraine
Supervisors: Dr. Nataliia Lymans'ka and Dr. Tetiana Vasyli'eva
Thesis: Phenotypic and genotypic properties of *Acidithiobacillus* spp. isolated from technogenic waste of Lviv-Volyn coal basin
- 2012–2016 B.Sc. in Biology, Faculty of Biology, Odesa I.I. Mechnikov National University, Odesa, Ukraine
Supervisor: Dr. Nataliia Lymans'ka and Dr. Tetiana Vasyli'eva
Thesis: Biological properties of acidophilic chemolithotrophic bacterial strains isolated from technogenic waste of Central Enrichment Factory of Lviv-Volyn coal basin

RESEARCH EXPERIENCE

- 10.2021–.... Institute of Technology, Faculty of Science and Technology, University of Tartu, Estonia
- 10.2019–02.2021 Department of Molecular Biology, Umeå University, Sweden
- 01.2018–06.2018 Department of Molecular Biology, Umeå University, Sweden

PUBLICATIONS

* Designates shared first authorship

- Brodiazhenko T**, Johansson MJ, Takada H, Nissan T, Hauryliuk V & Murina V (2018). Elimination of ribosome inactivating factors improves the efficiency of *Bacillus subtilis* and *Saccharomyces cerevisiae* cell-free translational systems. *Frontiers in microbiology*, 9, 3041.
- Kurata T, **Brodiazhenko T**, Alves Oliveira SR, Roghanian M, Sakaguchi Y, Turnbull KJ, Bulvas O, Takada H, Tamman H, Ainele A, Pohl R, Rejman D, Tenson T, Suzuki T, Garcia-Pino A, Atkinson GC, Hauryliuk V. RelA-SpoT Homolog toxins pyrophosphorylate the CCA end of tRNA to inhibit protein synthesis. *Mol Cell*. 2021 Aug 5;81(15):3160-3170.e9.
- Kurata T, Saha CK, Buttress JA, Mets T, **Brodiazhenko T**, Turnbull KJ, Awoyomi OF, Oliveira SRA, Jimmy S, Ernits K, Delannoy M, Persson K, Tenson T, Strahl H, Hauryliuk V, Atkinson GC. A hyperpromiscuous antitoxin protein domain for the neutralization of diverse toxin domains. *Proc Natl Acad Sci U S A*. 2022 Feb 8;119(6):e2102212119.
- Brodiazhenko T***, Turnbull KJ*, Wu KJY, Takada H, Tresco BIC, Tenson T, Myers AG, Hauryliuk V. Synthetic oxepanoprolinamide iboxamycin is active against *Listeria monocytogenes* despite the intrinsic resistance mediated by VgaL/Lmo0919 ABCF ATPase. *JAC Antimicrob Resist*. 2022 Jun 17;4(3):dlac061.

MANUSCRIPTS

- Zhang T, Tamman H, Wallant KC, Kurata T, LeRoux M, Srikant S, **Brodiazhenko T**, Cepauskas A., Talavera A., Marteens C, Atkinson GC, Hauryliuk V, Garcia-Pino A, Laub MT (2022). Direct activation of an innate immune system in bacteria by a viral capsid protein. *Nature*, accepted. bioRxiv doi.org/10.1101/2022.05.30.493996.

STIPENDS

- 10.2019–08.2020 Dora Plus T1.2 PhD student mobility stipend (Archimedes Foundation)

TEACHING EXPERIENCE

- 11.2016–12.2018 Lector in popular science project <15x4>, Odesa, Ukraine
04.2020–... Lector in science project <Genomics UA>, Kyiv, Ukraine
05.2022 Organizer of the course: Introduction to phage microbiology techniques, Institute of Technology, Faculty of Science and Technology, University of Tartu, Estonia

ELULOOKIRJELDUS

Nimi: Tetiana Brodiazhenko
Sünniaeg: 17/09/1995
Kodakondsus: Ukraina
Email: tetiana.brodiazhenko@ut.ee
Telefoninumber: +372 589 33705

TEADUSTEGEVUS

Minu teadustöö keskendub bakterite stressivastuse mehhanismide uurimisele. Täpsemalt uurin ma poomisvastuse keskse regulatoorse molekuli (p)ppGpp sünteesi. Lisaks uurin ma bakteriaalseid toksiin-antitoksiin süsteeme, mille mehhanismid on seotud poomisvastusega

HARIDUS

2018–2022 Doktorantuur Tartu Ülikooli Tehnoloogiainstituudis
Juhendajad: Professor Tanel Tenson ja Dr. Vasili Hauryliuk
Dokoritöö: Bakterite poomisvastuse ensüümide suhestumine toksiin-antitoksiin süsteemidega

2016–2018 Magistratuur Odessa Ülikooli bioloogia osakonnas Ukraina
Juhendajad: Dr. Nataliia Lymans'ka ja Dr. Tetiana Vasyl'ieva
Magistritöö: Lviv-Volyni kivisöejäätmete hoiualalt isoleeritud Acidithiobacillus spp. kirjeldamine

2012–2016 Bakalaureuseõpingud Odessa Ülikooli bioloogia osakonnas Ukraina
Juhendaja: Dr. Nataliia Lymans'ka ja Dr. Tetiana Vasyl'ieva
Bakalaureusetöö: Lviv-Volyni kivisöejäätmete hoiualalt isoleeritud atsidofiilsete kemolitotroofsete bakteritüvede bioloogiliste omaduste kirjeldamine

ERIALANE ENESETÄIENDUS

10.2021–..... Tartu Ülikooli Tehnoloogiainstituut, Eesti
10.2019–02.2021 Umeå Ülikooli Molekulaarbioloogia osakond, Rootsi
01.2018–06.2018 Umeå Ülikooli Molekulaarbioloogia osakond, Rootsi

PUBLIKATSIOONID

- Brodiazhenko T**, Johansson MJ, Takada H, Nissan T, Hauryliuk V & Murina V. (2018). Elimination of ribosome inactivating factors improves the efficiency of *Bacillus subtilis* and *Saccharomyces cerevisiae* cell-free translational systems. *Frontiers in microbiology*, 9, 3041.
- Kurata T, **Brodiazhenko T**, Alves Oliveira SR, Roghanian M, Sakaguchi Y, Turnbull KJ, Bulvas O, Takada H, Tamman H, Ainele A, Pohl R, Rejman D, Tenson T, Suzuki T, Garcia-Pino A, Atkinson GC, Hauryliuk V. RelA-SpoT Homolog toxins pyrophosphorylate the CCA end of tRNA to inhibit protein synthesis. *Mol Cell*. 2021 Aug 5; 81(15):3160-3170.e9.
- Kurata T, Saha CK, Buttress JA, Mets T, **Brodiazhenko T**, Turnbull KJ, Awoyomi OF, Oliveira SRA, Jimmy S, Ernits K, Delannoy M, Persson K, Tenson T, Strahl H, Hauryliuk V, Atkinson GC. A hyperpromiscuous antitoxin protein domain for the neutralization of diverse toxin domains. *Proc Natl Acad Sci U S A*. 2022 Feb 8;119(6):e2102212119.
- Brodiazhenko T***, Turnbull KJ*, Wu KJY, Takada H, Tresco BIC, Tenson T, Myers AG, Hauryliuk V. Synthetic oxepanoprolinamide iboxamycin is active against *Listeria monocytogenes* despite the intrinsic resistance mediated by VgaL/Lmo0919 ABCF ATPase. *JAC Antimicrob Resist*. 2022 Jun 17; 4(3):dlac061.

KÄSIKIRJAD

- Zhang T, Tamman H, Wallant KC, Kurata T, LeRoux M, Srikant S, **Brodiazhenko T**, Cepauskas A., Talavera A., Marteens C, Atkinson GC, Hauryliuk V, Garcia-Pino A, Laub MT (2022). Direct activation of an innate immune system in bacteria by a viral capsid protein. *Nature*, accepted. bioRxiv doi.org/10.1101/2022.05.30.493996.

PREEMIAD JA TOETUSED

10.2019–08.2020 Dora Plus T1.2 stipendium

ÕPETAMISKOGE MUS

- 11.2016–12.2018 Lektor populaarteaduslikus projektis „15x4“, Odessa, Ukraina
- 04.2020–.... Lektor populaarteaduslikus projektis „Genomics UA“, Kyiv, Ukraina
- 05.2022 Aitasin korraldada kursust „Introduction to phage microbiology techniques“, Tartu Ülikooli Tehnoloogiainstituut, Eesti

DISSERTATIONES TECHNOLOGIAE UNIVERSITATIS TARTUENSIS

1. **Imre Mäger.** Characterization of cell-penetrating peptides: Assessment of cellular internalization kinetics, mechanisms and bioactivity. Tartu 2011, 132 p.
2. **Taavi Lehto.** Delivery of nucleic acids by cell-penetrating peptides: application in modulation of gene expression. Tartu 2011, 155 p.
3. **Hannes Luidalepp.** Studies on the antibiotic susceptibility of *Escherichia coli*. Tartu 2012, 111 p.
4. **Vahur Zadin.** Modelling the 3D-microbattery. Tartu 2012, 149 p.
5. **Janno Torop.** Carbide-derived carbon-based electromechanical actuators. Tartu 2012, 113 p.
6. **Julia Suhorutšenko.** Cell-penetrating peptides: cytotoxicity, immunogenicity and application for tumor targeting. Tartu 2012, 139 p.
7. **Viktoryia Shyp.** G nucleotide regulation of translational GTPases and the stringent response factor RelA. Tartu 2012, 105 p.
8. **Mardo Kõivomägi.** Studies on the substrate specificity and multisite phosphorylation mechanisms of cyclin-dependent kinase Cdk1 in *Saccharomyces cerevisiae*. Tartu, 2013, 157 p.
9. **Liis Karo-Astover.** Studies on the Semliki Forest virus replicase protein nsP1. Tartu, 2013, 113 p.
10. **Piret Arukuusk.** NickFects—novel cell-penetrating peptides. Design and uptake mechanism. Tartu, 2013, 124 p.
11. **Piret Villo.** Synthesis of acetogenin analogues. Asymmetric transfer hydrogenation coupled with dynamic kinetic resolution of α -amido- β -keto esters. Tartu, 2013, 151 p.
12. **Villu Kasari.** Bacterial toxin-antitoxin systems: transcriptional cross-activation and characterization of a novel *mqsRA* system. Tartu, 2013, 108 p.
13. **Margus Varjak.** Functional analysis of viral and host components of alphavirus replicase complexes. Tartu, 2013, 151 p.
14. **Liane Viru.** Development and analysis of novel alphavirus-based multi-functional gene therapy and expression systems. Tartu, 2013, 113 p.
15. **Kent Langel.** Cell-penetrating peptide mechanism studies: from peptides to cargo delivery. Tartu, 2014, 115 p.
16. **Rauno Temmer.** Electrochemistry and novel applications of chemically synthesized conductive polymer electrodes. Tartu, 2014, 206 p.
17. **Indrek Must.** Ionic and capacitive electroactive laminates with carbonaceous electrodes as sensors and energy harvesters. Tartu, 2014, 133 p.
18. **Veiko Voolaid.** Aquatic environment: primary reservoir, link, or sink of antibiotic resistance? Tartu, 2014, 79 p.
19. **Kristiina Laanemets.** The role of SLAC1 anion channel and its upstream regulators in stomatal opening and closure of *Arabidopsis thaliana*. Tartu, 2015, 115 p.

20. **Kalle Pärn**. Studies on inducible alphavirus-based antitumour strategy mediated by site-specific delivery with activatable cell-penetrating peptides. Tartu, 2015, 139 p.
21. **Anastasia Selyutina**. When biologist meets chemist: a search for HIV-1 inhibitors. Tartu, 2015, 172 p.
22. **Sirle Saul**. Towards understanding the neurovirulence of Semliki Forest virus. Tartu, 2015, 136 p.
23. **Marit Orav**. Study of the initial amplification of the human papillomavirus genome. Tartu, 2015, 132 p.
24. **Tormi Reinson**. Studies on the Genome Replication of Human Papillomaviruses. Tartu, 2016, 110 p.
25. **Mart Ustav Jr**. Molecular Studies of HPV-18 Genome Segregation and Stable Replication. Tartu, 2016, 152 p.
26. **Margit Mutso**. Different Approaches to Counteracting Hepatitis C Virus and Chikungunya Virus Infections. Tartu, 2016, 184 p.
27. **Jelizaveta Geimanen**. Study of the Papillomavirus Genome Replication and Segregation. Tartu, 2016, 168 p.
28. **Mart Toots**. Novel Means to Target Human Papillomavirus Infection. Tartu, 2016, 173 p.
29. **Kadi-Liis Veiman**. Development of cell-penetrating peptides for gene delivery: from transfection in cell cultures to induction of gene expression *in vivo*. Tartu, 2016, 136 p.
30. **Ly Pärnaste**. How, why, what and where: Mechanisms behind CPP/cargo nanocomplexes. Tartu, 2016, 147 p.
31. **Age Utt**. Role of alphavirus replicase in viral RNA synthesis, virus-induced cytotoxicity and recognition of viral infections in host cells. Tartu, 2016, 183 p.
32. **Veiko Vunder**. Modeling and characterization of back-relaxation of ionic electroactive polymer actuators. Tartu, 2016, 154 p.
33. **Piia Kivipõld**. Studies on the Role of Papillomavirus E2 Proteins in Virus DNA Replication. Tartu, 2016, 118 p.
34. **Liina Jakobson**. The roles of abscisic acid, CO₂, and the cuticle in the regulation of plant transpiration. Tartu, 2017, 162 p.
35. **Helen Isok-Paas**. Viral-host interactions in the life cycle of human papillomaviruses. Tartu, 2017, 158 p.
36. **Hanna Hõrak**. Identification of key regulators of stomatal CO₂ signalling via O₃-sensitivity. Tartu, 2017, 260 p.
37. **Jekaterina Jevtuševskaja**. Application of isothermal amplification methods for detection of *Chlamydia trachomatis* directly from biological samples. Tartu, 2017, 96 p.
38. **Ülar Allas**. Ribosome-targeting antibiotics and mechanisms of antibiotic resistance. Tartu, 2017, 152 p.
39. **Anton Paier**. Ribosome Degradation in Living Bacteria. Tartu, 2017, 108 p.
40. **Vallo Varik**. Stringent Response in Bacterial Growth and Survival. Tartu, 2017, 101 p.

41. **Pavel Kudrin.** In search for the inhibitors of *Escherichia coli* stringent response factor RelA. Tartu, 2017, 138 p.
42. **Liisi Henno.** Study of the human papillomavirus genome replication and oligomer generation. Tartu, 2017, 144 p.
43. **Katrin Krõlov.** Nucleic acid amplification from crude clinical samples exemplified by *Chlamydia trachomatis* detection in urine. Tartu, 2018, 118 p.
44. **Eve Sankovski.** Studies on papillomavirus transcription and regulatory protein E2. Tartu, 2018, 113 p.
45. **Morteza Daneshmand.** Realistic 3D Virtual Fitting Room. Tartu, 2018, 233 p.
46. **Fatemeh Noroozi.** Multimodal Emotion Recognition Based Human-Robot Interaction Enhancement. Tartu, 2018, 113 p.
47. **Krista Freimann.** Design of peptide-based vector for nucleic acid delivery in vivo. Tartu, 2018, 103 p.
48. **Rainis Venta.** Studies on signal processing by multisite phosphorylation pathways of the *S. cerevisiae* cyclin-dependent kinase inhibitor Sic1. Tartu, 2018, 155 p.
49. **Inga Põldsalu.** Soft actuators with ink-jet printed electrodes. Tartu, 2018, 85 p.
50. **Kadri Künnapuu.** Modification of the cell-penetrating peptide PepFect14 for targeted tumor gene delivery and reduced toxicity. Tartu, 2018, 114 p.
51. **Toomas Mets.** RNA fragmentation by MazF and MqsR toxins of *Escherichia coli*. Tartu, 2019, 119 p.
52. **Kadri Töldsepp.** The role of mitogen-activated protein kinases MPK4 and MPK12 in CO₂-induced stomatal movements. Tartu, 2019, 259 p.
53. **Pirko Jalakas.** Unravelling signalling pathways contributing to stomatal conductance and responsiveness. Tartu, 2019, 120 p.
54. **S. Sunjai Nakshatharan.** Electromechanical modelling and control of ionic electroactive polymer actuators. Tartu, 2019, 165 p.
55. **Eva-Maria Tombak.** Molecular studies of the initial amplification of the oncogenic human papillomavirus and closely related nonhuman primate papillomavirus genomes. Tartu, 2019, 150 p.
56. **Meeri Visnapuu.** Design and physico-chemical characterization of metal-containing nanoparticles for antimicrobial coatings. Tartu, 2019, 138 p.
57. **Jelena Beljantseva.** Small fine-tuners of the bacterial stringent response – a glimpse into the working principles of Small Alarmone Synthetases. Tartu, 2020, 104 p.
58. **Egon Urgard.** Potential therapeutic approaches for modulation of inflammatory response pathways. Tartu, 2020, 120 p.
59. **Sofia Raquel Alves Oliveira.** HPLC analysis of bacterial alarmone nucleotide (p)ppGpp and its toxic analogue ppApp. Tartu, 2020, 122 p.
60. **Mihkel Örd.** Ordering the phosphorylation of cyclin-dependent kinase Cdk1 substrates in the cell cycle. Tartu, 2021, 228 p.

61. **Fred Elhi.** Biocompatible ionic electromechanically active polymer actuator based on biopolymers and non-toxic ionic liquids. Tartu, 2021, 140 p.
62. **Liisi Talas.** Reconstructing paleo-diversity, dynamics and response of eukaryotes to environmental change over the Late-Glacial and Holocene period in lake Lielais Svētiņū using sedaDNA. Tartu, 2021, 118 p.
63. **Livia Matt.** Novel isosorbide-based polymers. Tartu, 2021, 118 p.
64. **Koit Aasumets.** The dynamics of human mitochondrial nucleoids within the mitochondrial network. Tartu, 2021, 104 p.
65. **Faiza Summer.** Development and optimization of flow electrode capacitor technology. Tartu, 2022, 109 p.
66. **Olavi Reinsalu.** Cancer-testis antigen MAGE-A4 is incorporated into extracellular vesicles and is exposed to the surface. Tartu, 2022, 130 p.